What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2025-03-05 compared with 2024-03-13 · 1764 added, 1319 removed, 77 unchanged (98% of the section changed)

are a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment

of cancer and rare diseases.

We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements

to established mechanisms in order to create new development opportunities.

We prioritize creativity, diverse perspectives, integrity

and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

portfolio includes two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator,

OK-432, which was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer

therapeutic agent.

This cell therapy is currently approved in Japan and Taiwan for LMs and multiple oncologic indications.

We have secured

worldwide rights to the asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications.

was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil®

in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical).

We are currently developing TARA-002 in non-muscle

invasive bladder cancer, or NMIBC, and in LMs.

lead oncology program is TARA-002 in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has

not spread into the bladder muscle.

Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately

80% of bladder cancer diagnoses.

We are a New York City based

clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases.

We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in

order to create new development opportunities.

We prioritize creativity, diverse perspectives, integrity and tenacity to expedite our

goal of bringing life-changing therapies to people with limited treatment options.

Our portfolio includes two development programs utilizing TARA-002,

an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally granted marketing approval by the Japanese

Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent.

TARA-002 is currently approved in Japan and Taiwan for

lymphatic malformations, or LMs, and multiple oncologic indications.

We have secured worldwide rights to the asset excluding Japan and

Taiwan and are exploring its use in oncology and rare disease indications.

TARA-002 was developed from the same master cell bank of genetically

distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical).

We are currently developing TARA-002 in non-muscle invasive bladder cancer, or NMIBC, and in LMs.

Our lead oncology program

is TARA-002 in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder

Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer

Approximately 65,000 patients are diagnosed with NMIBC in the United States each year.

therapeutics have been approved for NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical Bacillus Calmette–Guérin,

The mechanism of action of TARA-002 is similar in some ways to that of BCG.

TARA-002 and BCG are both intravesically administered,

elicit a Th1 type immune response and produce a locally-activated generally similar array of cytokines and immune cells.

are conducting a Phase 1 open-label clinical trial to evaluate TARA-002 in treatment-naïve and treatment-experienced NMIBC patients

with carcinoma in situ, or CIS, and high-grade papillary tumors, or Ta, known as the ADVANCED-1 trial.

In the initial dose escalation

phase of the trial, patients received six weekly intravesical doses of TARA-002, evaluating the 10KE, 20KE and 40KE doses (Klinische

Einheit, or KE, is a German term indicating a specified weight of dried cells in vial).

The primary objective of the trial is to evaluate

the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended Phase

In April 2023, we announced positive preliminary data from the Phase 1a dose escalation component of the ongoing ADVANCED-1 trial

through the 40KE dose, in which TARA-002 indicated favorable tolerability and anti-tumor activity in NMIBC patients.

A maximum tolerated

dose was not determined, and dose escalation remains ongoing in exploratory cohorts.

Preliminary data from the

ADVANCED-1 trial suggested that intravesical TARA-002 was generally well tolerated at the three dose levels evaluated in the initial phase

of the trial, and no dose limiting toxicities were observed.

The Company has selected the 40KE dose for use in subsequent clinical trials.

The majority of reported adverse events were Grades 1 and 2 across all dose levels, and treatment-related adverse events, as assessed

by study investigators, were in line with typical responses to bacterial immunopotentiation and included fatigue, headache, fever and

The most common urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning, incomplete emptying, and

bladder spasm.

Most bladder irritations resolved soon after administration, or in a few hours to a few days.

A total of nine patients

were enrolled in the dose escalation portion of the study through the 40KE dose.

Of those, three patients with CIS,

one of whom was a heavily pre-treated BCG-unresponsive patient, achieved a complete response at the 20KE dose, and tumor regression

was observed in the other two patients.

Results from six patients with high-grade, non-invasive papillary, or HGTa, tumors showed five

of six patients with high-grade recurrence free survival, or HGRFS, at week 12.

The patient who did not achieve HGRFS was dosed at 10KE,

the lowest dose of TARA-002 offered in the trial.

The ongoing open-label expansion trial, or ADVANCED-1EXP, is evaluating

intravesical TARA-002 at the 40KE dose in up to 12 CIS patients, including BCG-naïve, BCG-unresponsive, and BCG-inadequately treated

Dosing is progressing in the trial, and we anticipate having preliminary data from this trial in the first half of 2024.

Based on the preliminary

results of ADVANCED-1, we are proceeding with the clinical development of TARA-002 for the treatment of NMIBC.

In September 2023, we

initiated ADVANCED-2, a Phase 2 open-label trial evaluating intravesical TARA-002 in at least 102 patients with high-grade CIS.

A of the Phase 2 trial is expected to enroll 27 patients with CIS (± Ta/T1), BCG-Naïve or BCG-experienced, who have not received

intravesical BCG for at least 24 months prior to CIS diagnosis.

Cohort B of the Phase 2 trial is expected to enroll 75-100 patients with

BCG-unresponsive CIS (± Ta/T1).

The Company expects to share preliminary results from a pre-planned risk-benefit analysis of the

ongoing Phase 2 open-label ADVANCED-2 trial in the second half of 2024.

The analysis is expected to include approximately 10 patients

who are six-month evaluable.

addition, we continue to conduct pre-clinical studies on TARA-002 to better characterize the mechanism of action to help us understand

how TARA-002 may perform in potential combinations with other agents used to treat NMIBC.

We use pre-clinical data to help us define

other cancer targets for TARA-002, both within urothelial cancer and other types of cancer affecting different parts of the body.

We are also pursuing TARA-002 in LMs, which are rare, non-malignant

cysts of the lymphatic vascular system that primarily form in the head and neck region of children before the age of two.

In July 2020,

the FDA granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs and in May 2022 the European Medicines Agency

granted orphan drug designation to TARA-002 for the treatment of LMs.

In addition to the clinical experience in Japan, we have secured

the rights to a dataset from one of the largest ever conducted Phase 2 trials in LMs, in which OK-432 was administered via a compassionate

use program led by the University of Iowa to over 500 pediatric and adult patients.

We have an investigational new drug application for

LMs with the Vaccines and Related Products Division of the FDA, or Vaccines Division.

2023, we initiated STARBORN-1 is a Phase 2 single-arm,

open-label, prospective clinical trial to evaluate the safety and efficacy of intracystic injection of TARA-002 for the treatment of

macrocystic and mixed-cystic LMs (≥ 50% macrocystic disease) in participants six months to less than 18 years of age.

an age de-escalation safety lead-in, the trial will enroll approximately 30 patients who will receive up to four injections of

TARA-002 spaced approximately six weeks apart.

primary endpoint of the trial is the proportion of participants with macrocystic LMs and mixed-cystic LMs who demonstrated clinical success,

defined as having either a complete response (90% to 100% reduction from baseline in total LM volume) or substantial response (60% to

less than 90% reduction in total LM volume) as measured by axial imaging.

The third development program in our portfolio is intravenous, or IV,

Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral nutrition, or PN.

FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.

We have conducted

a two-part prevalence study to enhance our understanding of the PN patient population.

The first, or retrospective, part of the prevalence

study was completed in September 2021, when we reported results that supported that there was a significant unmet medical need in patients

dependent on PN.

We have concluded the second, or prospective part, of the prevalence study, which is a multi-center, cross-sectional

observational study that assessed the prevalence of choline deficiency in patients dependent on PN.

We shared these results with the FDA

to inform our discussion on next steps for the IV Choline Chloride program.

There are currently no IV formulations of choline available

or in development for PN patients.

Very few new therapeutics have been

approved for NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical Bacillus Calmette-Guérin,

Following the completion of Phase 1a and 1b clinical trials to

evaluate safety, preliminary efficacy and the dosing of TARA-002, at the 40KE (Klinische Einheit, or KE, is a German term indicating a

specified weight of dried cells in vial) dose level, we initiated and are currently conducting our ADVANCED-2 clinical trial.

is a Phase 2 open-label trial evaluating intravesical TARA-002 in at least 102 patients with high-grade carcinoma in situ, or CIS in the

U.S., Canada, Argentina, and Ukraine.

Cohort A of the Phase 2 trial is expected to enroll 27 patients with CIS (± Ta/T1 with Ta

defined as non-invasive papillary carcinoma and T1 as defined as carcinoma invading the lamina propria), BCG-Naïve or BCG-Exposed,

who have not received intravesical BCG for at least 24 months prior to CIS diagnosis.

Cohort B of the Phase 2 trial is expected to enroll

75-100 patients with BCG-Unresponsive CIS (± Ta/T1) and is expected to be registrational based on the FDA’s August 2024 Draft

Guidance on BCG-Unresponsive Nonmuscle Invasive Bladder Cancer:

Developing Drugs and Biological Products for Treatment.

We expect to complete Cohort A (BCG-Naïve or BCG-Exposed)

of the clinical trial and share 12-month interim data by mid-2025 and complete a interim analysis in Cohort B (BCG-Unresponsive) of the

clinical trial by the end of 2025.

The interim analysis will include data from approximately 25 six-month evaluable patients.

In addition to the ADVANCED-2

trial, we plan to continue to explore the anti-tumor activity related to the administration of TARA-002 via systemic administration.

continue to believe that combination therapy may play a meaningful role in the NMIBC treatment paradigm and intend to evaluate TARA-002

in combination with other therapies.

Given what we have observed to date of TARA-002’s mechanism of action and safety profile, we

believe it has strong potential as a combination agent, and we continue to evaluate potential combination therapy options for our clinical

We also continue to conduct non-clinical studies on TARA-002 to better characterize the mechanism of action to help us understand

how TARA-002 may perform in potential combinations with other agents used to treat NMIBC, and to help us define other cancer targets for

TARA-002, both within urothelial cancer and other types of cancer affecting different parts of the body.

We are also pursuing intravenous, or IV, Choline Chloride, an

investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition

Choline is a known important substrate for phospholipids that are critical for healthy liver function and also plays an important

role in modulating gene expression, cell membrane signaling, brain development, neurotransmission, muscle function and bone health.

patients are unable to synthesize choline from enteral nutrition sources, and there are currently no available PS formulations containing

Every year in the U.S.

there are approximately 90,000 people who require PS at home and of those approximately 30,000 are on

long-term PS.

IV Choline Chloride has the potential to become the first FDA-approved IV choline formulation for PS patients.

An IV formulation of choline

is recommended for patients on parenteral nutrition, or PN, by the American Society for Parenteral and Enteral Nutrition, or ASPEN, in

their Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi–Trace Element Products, as well as

by the European Society for Clinical Nutrition and Metabolism, or ESPEN, in their Guideline on Home Parenteral Nutrition.

IV Choline Chloride

has been granted Orphan Drug Designation by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term

Patent and Trademark Office, or USPTO, has issued us a U.S.

patent claiming a choline composition and a U.S.

patent claiming

a method for treating choline deficiency with a choline composition, each with a term expiring in 2041.

In April 2024, we announced

alignment with the FDA on a registrational path forward for IV Choline Chloride.

Previously, we had been pursuing an indication in intestinal

failure-associated liver disease, or IFALD, and following feedback from the FDA, are pursuing a broader indication as a source of choline

when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Feedback from the FDA on our IV Choline Chloride program

indicated that a single study with an endpoint of restoring choline levels in PS patients could serve as the basis for a regulatory submission

for IV Choline Chloride.

We plan to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients

on long-term PS and intend to initiate THRIVE-3, a registrational Phase 3 clinical trial in the first half of 2025.

THRIVE-3 is a seamless

Phase 2b/3 trial with a dose confirmation portion (n=24) followed by a double-blinded, randomized, placebo-controlled portion to assess

the efficacy and safety of IV Choline Chloride over 24 weeks in adolescents and adults on long-term PS when oral or enteral nutrition

is not possible, insufficient, or contraindicated (n=100).

The primary endpoint of the clinical trial is a pharmacokinetic, or PK, endpoint

measuring the change from baseline in plasma choline concentration.

We also plan to include a number of secondary endpoints related to

liver, bone, and memory.

The FDA has also granted IV Choline Chloride Fast Track Designation as a source of choline when oral or enteral

nutrition is not possible, insufficient, or contraindicated.

In September 2024, we presented the results of THRIVE-1, a prospective,

observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on PS in the U.S., U.K, and

Europe at the ESPEN Congress.

The study found that 78% of patients who are dependent on PS were choline deficient, and that 63% of choline

deficient participants had liver dysfunction, including steatosis, cholestasis and hepatobiliary injury, underscoring the need for IV

Choline supplementation in this patient population.

We are also pursuing TARA-002

in LMs, which are rare, non-malignant cysts of the lymphatic vascular system that primarily form in the head and neck region of children

before the age of two.

In July 2020, the FDA granted Rare Pediatric Disease Designation for TARA-002 for the treatment of LMs and in May

2022 the European Commission granted Orphan Drug Designation to TARA-002 for the treatment of LMs.

In addition to the clinical experience

in Japan, we have secured the rights to a dataset from one of the largest ever conducted Phase 2 trials in LMs, in which OK-432 was administered

via a compassionate use program led by the University of Iowa to over 500 pediatric and adult patients.

We have an open investigational

new drug application, or IND, for TARA-002 in LMs with the Vaccines and Related Products Division of the FDA, or Vaccines Division.

In October 2023, we initiated STARBORN-1, which is a Phase 2 single-arm,

open-label, prospective clinical trial to evaluate the safety and efficacy of intracystic injection of TARA-002 for the treatment of macrocystic

and mixed-cystic LMs (≥ 50% macrocystic disease) in participants six months to less than 18 years of age in the U.S.

Including an age

de-escalation safety lead-in, the clinical trial will enroll approximately 30 patients who will receive up to four injections of TARA-002

spaced approximately six weeks apart.

The primary endpoint of the clinical trial is the proportion of participants with macrocystic LMs

and mixed-cystic LMs who demonstrated clinical success, defined as having either a complete response (90% to 100% reduction from baseline

in total LM volume) or substantial response (60% to less than 90% reduction in total LM volume) as measured by axial imaging.

In September 2024, we announced interim data from the first safety

cohort in the STARBORN-1 trial.

Of three patients treated in the first cohort, which enrolled individuals six years to less than 18 years

of age, two patients treated with TARA-002 achieved a complete response after receiving one injection of TARA-002;

the responses were

seen in a patient with a macrocystic LM and a patient with a maxillofacial cyst called a ranula.

The tolerability observed in this cohort

was consistent with patients’ historical experience with OK-432 and included treatment emergent adverse events, or TEAEs, of pain,

swelling, fatigue and body temperature increases.

All TEAEs were mild to moderate and resolved.

We expect to provide an interim update from our STARBORN-1 trial by the end of the first half of 2025.

We believe TARA-002 may also have the potential to be used to treat

other maxillofacial cysts based on the historical literature from the TARA-002 predecessor, OK-432, as well as recent data from the STARBORN-1

trial in which the one pediatric patient with a ranula achieved a complete response after a single 1KE injection of TARA-002.

While completing

STARBORN-1 in LMs is our priority, we believe there may be an opportunity in the future to explore the potential of TARA-002 to treat

different types of maxillofacial cysts.

We have devoted substantial efforts to the development of these programs

and do not have any approved products and have not generated any revenue from product sales.

Neither TARA-002 nor IV Choline Chloride have

been approved for use for any indications.

We do not expect to generate revenues in the near-term, and it is possible we may never generate

revenues in the future.

To finance our current strategic plans, including the conduct of ongoing and future clinical trials and further

research and development costs, we will need to raise additional capital.

Management’s Discussion and Analysis

of Financial Condition and Results of Operations—Liquidity and Capital Resources” for additional information about our liquidity

and capital resource needs.

Product Candidate Pipeline

following chart summarizes the current status of our product candidate pipeline:

Granted Rare Pediatric Disease Designation for the treatment of LMs

Orphan Drug Designations by the U.S.

Corporate Strategy:

are an oncology and rare disease company focused on applying modern scientific advancements to established mechanisms to deliver efficient

de-risked clinical programs.

Leveraging the drug development and commercialization experience of our management team, our goal is to

build a leading biopharmaceutical company focused on bringing life-saving therapies to patients with significant unmet needs.

key initiatives are listed below:

Progress clinical program supporting TARA-002 for the treatment of NMIBC

Complete the ongoing Phase

1 expansion ADVANCED-1EXP clinical trial to further assess the safety and tolerability of TARA-002 in patients with high-grade NMIBC, and progress

the Phase 2 ADVANCED-2 clinical trial to assess the safety and anti-tumor activity of TARA-002 in both BCG-unresponsive and BCG-naïve

NMIBC patients with CIS.

Progress the Phase 2 clinical trial of TARA-002 in patients with macrocystic and mixed-cystic LMs

Based on the robust dataset for the originator product OK-432 in LMs

and the full Clinical Study Report, or CSR, of the randomized Phase 2 clinical trial of OK-432 in LMs led by the University of Iowa, we

are encouraged by the potential for TARA-002 to treat patients with LMs.

We initiated the STARBORN-1 Phase 2 trial evaluating TARA-002

in pediatric patients with macrocystic and mixed-cystic LMs and expect to progress the initial safety lead-in cohorts of the trial this

Align with the FDA on the path forward for IV Choline Chloride for patients receiving PN

We continue to engage with

the FDA to define a path forward for IV Choline Chloride, including understanding the requirements for registrational clinical data needed

for a potential NDA filing for approval.

Explore opportunities to expand our pipeline of uses for TARA-002 alone and in combination with other therapies

are exploring the use of TARA-002 in combination with other therapies and are working to identify additional opportunities to develop

TARA-002 in indications beyond NMIBC and LMs.

We are conducting non-clinical experiments and modeling to better characterize the potential

benefits of combination therapy with TARA-002, particularly in NMIBC.

In addition, our leadership team has a strong track record of licensing,

acquiring and optimizing product candidates and we intend to leverage this skill set to identify potential combination

opportunities for TARA-002, in NMIBC and other oncology indications.

The immunological activity of TARA-002’s originator product,

OK-432, has been effectively interrogated in patients in numerous indications.

We plan to continue to carefully evaluate the case reports

and the literature and perform non-clinical characterization studies to better understand the mechanism of action of TARA-002 and its

potential activity in indications beyond NMIBC and LMs in which there is unmet need.

our lead program, is an investigational cell therapy developed from the master cell line of the same genetically distinct Streptococcus

pyogenes (group A, type 3) Su strain as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan by Chugai Pharmaceutical.

We are using the same regulatory starting materials as OK-432 and manufacture TARA-002 using an updated version of the same proprietary

processes used to manufacture OK-432.

We have designated this product candidate as TARA-002 in order to differentiate the regulatory

path in the United States and other geographies from that of OK-432 in Japan.

entered into an agreement with Chugai Pharmaceutical in June 2019, as amended in July 2020, to support our development of TARA-002.

The agreement provides us with exclusive access to certain materials and documents relating to OK-432 including the master cell bank

of Streptococcus pyogenes used in the manufacturing of OK-432.

Additionally, the agreement provides technical support during a

certain period.

We have utilized the materials, proprietary manufacturing process and technical support provided by Chugai

Pharmaceutical to produce TARA-002 at a current Good Manufacturing Practices-, or cGMP-, compliant facility in the United States.

Neither TARA-002 nor IV Choline Chloride

have been approved for use for any indication by the FDA.

We do not expect to generate revenues in the near-term, and it is possible we

may never generate revenues in the future.

To finance our current strategic plans, including the conduct of ongoing and future clinical

trials and further research and development costs, we will need to raise additional capital.

Management’s Discussion

and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” for additional information

about our liquidity and capital resource needs.

Our Product Candidate Pipeline

The following chart summarizes

the current status of our product candidate pipeline:

Orphan Drug Designations by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term PN and Fast Track

Designation as a source of choline when oral or enteral nutrition is not possible, insufficient, or contraindicated.

granted Rare Pediatric Disease designation by the FDA and Orphan Drug Designation by the European Commission for the treatment of LMs.

Trial also includes BCG-Exposed patients.

Our Corporate Strategy:

We are an oncology and rare

disease company focused on applying modern scientific advancements to established mechanisms to deliver efficient de-risked clinical programs.

Leveraging the drug development experience of our management team, our goal is to build a leading biopharmaceutical company focused on

bringing life-saving therapies to patients with significant unmet needs.

Our current key initiatives are listed below:

Progress the registrational clinical

trial of TARA-002 for the treatment of BCG-Unresponsive NMIBC and intend to discuss with the FDA a protocol for a registrational trial

evaluating TARA-002 in BCG-Naïve NMIBC

Progress the Phase 2 ADVANCED-2 registrational trial to assess

the safety and anti-tumor activity of TARA-002 in BCG-Unresponsive NMIBC patients with CIS and complete the proof-of-concept cohort of

the clinical trial evaluating TARA-002 in BCG-Naïve NMIBC patients with CIS.

Discuss with the FDA the design of, and initiate, a

registrational trial evaluating TARA-002 in patients with BCG-Naïve NMIBC.

Expand the NMIBC program for TARA-002

into systemic priming dosing and combination therapy

Complete non-clinical studies

to determine the best approach to administering a systemic priming dose of TARA-002 prior to intravesical installation of TARA-002 in

NMIBC patients.

Define the appropriate combination approach for TARA-002 and initiate a proof-of-concept study to evaluate TARA-002 in

combination with a checkpoint inhibitor for the treatment of BCG-Unresponsive NMIBC.

Initiate the registrational seamless

Phase 2b/3 trial evaluating IV Choline Chloride in patients receiving PS

We intend to initiate the

Phase 2b/3 THRIVE-3 registrational trial evaluating IV Choline Chloride in patients receiving PS in the first half of 2025.

Progress the Phase 2 clinical trial of

TARA-002 in patients with macrocystic and mixed-cystic LMs;

continue exploration of TARA-002 in other maxillofacial cysts

Based on the robust dataset for the originator product OK-432

in LMs and the full Clinical Study Report, or CSR, of the randomized Phase 2 clinical trial of OK-432 in LMs led by the University of

Iowa, we are encouraged by the potential for TARA-002 to treat patients with LMs.

We initiated the STARBORN-1 Phase 2 trial evaluating

TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs and expect to progress the initial safety lead-in and expansion cohorts

of the clinical trial in 2025.

Given the extensive body of literature of the use of OK-432 in the treatment of various maxillofacial cysts,

we plan to develop a clinical program to explore the potential of TARA-002 in maxillofacial cysts.

Build our operational capabilities to

successfully commercialize our oncology and rare disease programs

As we approach regulatory

filings and possible approvals of our oncology and rare disease investigational therapies, we intend to build our commercial infrastructure

to successfully launch and commercialize our products in key geographies where we can maximize value.

Across the rare disease populations

(LMs and patients on PS) as well as bladder cancer, where the patient population is large, a high volume of patients are concentrated

in a small number of centers of excellence.

We believe this concentration of treatment centers will potentially enable us to efficiently

cover our addressable market with a relatively small commercial footprint.

Across our rare disease programs, there is significant unmet

need and no available FDA-approved therapies to meet the needs of these patients currently.

In NMIBC, there is also a significant unmet

need, and we believe TARA-002’s important attributes, such as fast, simple administration by a nurse with no cumbersome additional

steps or required safety protocols and a favorable tolerability profile, will position the potential therapy favorably with patients and

physicians versus other treatment options.

TARA-002, our lead program,

is an investigational cell therapy developed from the master cell line of the same genetically distinct Streptococcus pyogenes (group

A, type 3) Su strain as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan by Chugai Pharmaceutical.

We are using the

same regulatory starting materials as OK-432 and manufacture TARA-002 using an updated version of the same proprietary processes used

to manufacture OK-432.

We have designated this product candidate as TARA-002 in order to differentiate the regulatory path in the United

States and other geographies from that of OK-432 in Japan.

We entered into an agreement

with Chugai Pharmaceutical in June 2019, as amended in July 2020, to support our development of TARA-002.

The agreement provides us with

exclusive access to certain materials and documents relating to OK-432 including the master cell bank of Streptococcus pyogenes used in

the manufacturing of OK-432.

Additionally, the agreement provides technical support during a certain period.

We have utilized the materials,

proprietary manufacturing process and technical support provided by Chugai Pharmaceutical to support a contract development and manufacturing

organization, or CDMO, in the production of TARA-002 at a current Good Manufacturing Practices, or cGMP, compliant facility in the United

Under the agreement with Chugai Pharmaceutical, we have sole responsibility for the development and commercialization of TARA-002

worldwide, excluding Japan and Taiwan.

This agreement is exclusive through June 17, 2030, or following any termination of the

agreement by either party.

Japan, OK-432 is indicated for:

This agreement is exclusive through June 17, 2030, or following any termination of the agreement

by either party.

In Japan, OK-432 is indicated

the treatment of lymphangiomas (lymphatic malformations);

the prolongation of survival time in patients

with gastric cancer (postoperative cases) or primary lung cancer in combination with chemotherapy;

and the reduction of cancerous pleural

effusion or ascites in patients with lung cancer or gastrointestinal cancer respectively, head and neck cancer (maxillary cancer, laryngeal

cancer, pharyngeal cancer, and tongue cancer) and thyroid cancer that are resistant to other drugs.

are developing TARA-002 for the treatment of NMIBC and LMs initially in the United States, and plan to also seek approval in Europe and

other regions in the future and may also explore additional indications where its utility as an immunopotentiator has been hypothesized

to be of therapeutic benefit.

the prolongation of survival time in patients with gastric cancer (postoperative

cases) or primary lung cancer in combination with chemotherapy;

and the reduction of cancerous pleural effusion or ascites in patients

with lung cancer or gastrointestinal cancer respectively, head and neck cancer (maxillary cancer, laryngeal cancer, pharyngeal cancer,

and tongue cancer) and thyroid cancer that are resistant to other drugs.

We are developing TARA-002

for the treatment of NMIBC and LMs initially in the United States, and plan to also seek approval in other regions in the future and may

also explore additional indications where its utility as an immunopotentiator has been hypothesized to be of therapeutic benefit.

TARA-002 in NMIBC

Disease Overview

Bladder cancer is the sixth

3 unchanged sentences

There are three subtypes of NMIBC:

Ta (non-invasive papillary carcinoma), Tis (CIS), and T1 (carcinoma invading the lamina propria).

non-invasive papillary carcinoma, or Ta, CIS, and carcinoma invading the lamina propria, or T1.

Among the types of NMIBC, Ta accounts

for most NMIBC cases (70%), whereas T1 and CIS account for 20% and 10%, respectively.

are approximately 65,000 incident cases of NMIBC in the United States every year, and based upon currently available data we believe

that approximately 45% (approximately 30,000) are made up of High-Grade tumor types that are considered higher risk, and therefore candidates

for immunotherapies, such as TARA-002.

In addition, NMIBC has one of the highest rates of recurrence with three-year rate estimated at

Treatment for NMIBC is typically targeted to reduce unresectable persistence,

recurrence after resection and to prevent disease progression to muscle-invasive bladder cancer.

The initial treatment for NMIBC includes

cystoscopy and complete transurethral resection of the bladder tumor, or TURBT, for papillary Ta or T1, or biopsy for CIS.

A single postoperative

instillation of intravesical chemotherapy is recommended in patients with low risk of progression, and for patients with intermediate

and high-risk disease, a longer course of intravesical therapy is administered.

The most efficacious intravesical agent to date has been

BCG, a live attenuated form of Mycobacterium bovis .

BCG has been the subject of multiple supply shortages in the US in the past

decade due to the inability to meet demand to treat the large population of patients with NMIBC.

There has been a significant increase

in bladder cancer recurrence and progression with an escalated number of patients who require cystectomy.

As such, with the current BCG

shortage and limited effective alternate therapies or dosing strategies, there continues to be a significant unmet need for treatment

options for patients with NMIBC.

are currently conducting our ADVANCED-1EXP and ADVANCED-2 clinical trials.

ADVANCED-1EXP,

an open-label expansion trial, is evaluating intravesical TARA-002 at the 40KE dose in up to 12 CIS patients, including BCG-naïve,

BCG-unresponsive, and BCG-inadequately treated patients.

Dosing is progressing in the trial, and we anticipate having preliminary data

from the trial in the first half of 2024.

is a Phase 2 open-label trial evaluating intravesical TARA-002 in at

least 102 patients with high-grade CIS.

Cohort A of the Phase 2 trial is expected to enroll 27 patients with CIS (± Ta/T1), BCG-Naïve

or BCG-experienced, who have not received intravesical BCG for at least 24 months prior to CIS diagnosis.

Cohort B of the Phase 2 trial

is expected to enroll 75-100 patients with BCG-unresponsive CIS (± Ta/T1).

The Company expects to share preliminary results from

a pre-planned risk-benefit analysis of the ongoing Phase 2 open-label ADVANCED-2 trial in the second half of 2024.

The analysis is expected

to include approximately 10 patients who are six-month evaluable.

continue to conduct pre-clinical studies on TARA-002 to better characterize the mechanism of action to help us understand how TARA-002

may perform in potential combinations with other agents used to treat NMIBC.

In addition, we use pre-clinical data to help us define

other cancer targets for TARA-002 both within the urothelial cancer space and other types of cancer affecting different parts of the

October 2021, we announced that the Office of Tissues and Advanced Therapies Division, or the OTAT Division, of the FDA’s Center

for Biologics Evaluation and Research, or CBER, cleared our Investigational New Drug application for TARA-002 in NMIBC.

had ongoing dialogue with the FDA to align on trial design of ADVANCED-1 and ADVANCED-2, as well as the potential combination trial we

may pursue with TARA-002 in NMIBC.

Manufacturing

We manufacture TARA-002 using an equivalent, but modernized, proprietary

manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting with a master cell line propagated by us but utilizing

the same genetically distinct strain of Streptococcus pyogenes (A group, type 3) Su strain as OK-432.

We have contracted a cGMP-compliant

contract development and manufacturing organization, or CDMO, to manufacture TARA-002.

The International

Society for the Study of Vascular Anomalies classifies LMs as either macrocystic, microcystic, or mixed-cystic.

Macrocystic and microcystic

LMs are differentiated by the size of the fluid-containing portion of the malformation.

Macrocystic LMs are characteristically large,

fluid-filled cysts with a thin endothelial lining.

Macrocystic LMs are composed of cysts greater than 2 cubic centimeters in size and

present as a soft, fluid-filled swelling beneath normal or slightly discolored skin.

Macrocystic LMs are usually located in the antero-lateral

cervical region of the neck;

however, it is possible for this type of LM to originate in other areas of the body.

In contrast, microcystic

LMs have very limited internal space with a thick irregular endothelial lining.

Microcystic LMs are comprised of cysts less than 2 cubic

centimeters in size and are often composed of micro-lymphatic channels that integrate and infiltrate normal soft tissue.

LMs can involve both superficial and deep aspects including muscle and bone.

Microcystic LMs can thicken or swell causing enlargement

of surrounding soft tissue and bones and can be found on any area of the skin or mucous membrane.

Mixed-cystic LMs are comprised of varying

degrees of both macrocystic and microcystic LMs.

the exact prevalence of LMs is not known, in the United States, the condition is thought to be present in approximately one in every

4,000 live births and we believe there are approximately 1,400-1,800 LM cases per year.

are no approved pharmacotherapies for LMs, except in Japan and Taiwan where OK-432 is approved.

In these countries, OK-432 has been the

standard of care for LMs for over 25 years.

of LMs varies depending on the symptoms and complications that present themselves.

The standard of care outside Japan and Taiwan for

the treatment of LMs is either a partial or complete surgical excision of the cysts.

While surgery is the standard approach to the treatment

of LMs in the head and neck, the region is a difficult area to operate on because of the large number of important anatomical structures

Major venous and arterial trunks travel through the neck, as do important nerves.

Surgery on such malformations frequently

results in high rates of recurrence and complications including life-long chronic conditions, such as damage to nerves and other important

structures of the head and neck.

Data on OK- 432, predecessor therapy to TARA-002

When TARA-002 is administered, it is hypothesized that innate and adaptive

immune cells within the cyst or tumor are activated and produce a strong immune cascade.

Neutrophils, monocytes, and lymphocytes infiltrate

the abnormal cells and various cytokines, including interleukins IL-2, IL-6, IL-10, IL-12, interferon, or IFN,-gamma, and tumor necrosis

factor, or TNF,-alpha are secreted by immune cells to induce a strong inflammatory reaction and destroy the abnormal cells.

these immune activities induce a strong local inflammatory reaction in the cyst wall, resulting in fluid drainage, shrinkage and fibrotic

adhesion of the cyst.

A randomized, Phase 2 clinical trial led by the University of Iowa

studied the use of OK-432 in patients with LM from 1998 to 2005.

Most eligible subjects were between 6 months and 18 years of age with

macrocystic or mixed-cystic LMs (with ≥ 50% macrocytic disease) of the head and/or neck.

There were three treatment groups:

treatment, or ITG, delayed treatment, or DTG, and open label treatment group.

The immediate treatment group received treatment with OK-432

upon diagnosis.

The delayed treatment group received OK-432 treatment following a six-month observation period;

the cross-over design

was intended to investigate spontaneous resolution.

The open-label treatment group included infants younger than six months of age, adults

older than 18 years of age, patients with LMs involving sites other than the head and neck (such as the axilla, thorax, and extremities),

and patients treated on an emergent basis.

The open label treatment group were treated immediately with OK-432.

Response to therapy was

measured by quantitating change in lesion size.

Clinical success was defined as a complete (90% to 100%) or substantial (60% to 89%) response

to treatment based on radiographically confirmed shrinkage in lesions.

presented in this report were based on a retrospective analysis of source verified data that included the full dataset of subjects enrolled

in the Phase 2 randomized clinical trial between January 1998 and August 2005, including data in the published study (Smith et al.

that included subjects enrolled between January 1998 and November 2004.

310 subjects were enrolled with intent to treat:

246 subjects were randomized to the immediate (ITG, N=171) and delayed (DTG, N=75) treatment

64 subjects were nonrandomized and assigned to the open-label group.

Analysis of the primary efficacy endpoint (N=150) demonstrated

clinical success (complete and/or substantial response) in 69% of patients in the ITG 6 months after enrollment, while 7.5% of patients

in the DTG experienced spontaneous regression of a LM during this time interval (p < 0.0001)).

When the results were analyzed by lesion

type across all treatment groups, a successful outcome was observed in 84% and 60% of patients with macrocystic and mixed-cystic LM,

respectively.

None of the patients with microcystic LM demonstrated clinical success with OK-432 therapy.

The results of the retrospective

analysis were consistent with the results observed in the original analysis (Smith et al.

69% of patients in the immediate treatment group had a complete or substantial response to OK-432, meeting the primary endpoint, while

7.5% of patients in the delayed treatment group had a complete or substantial response after six months of observation and before treatment.

Success was defined as complete or substantial response.

data prior to dosing with OK-432.

After dosing, the clinical success rate was 66%, which was not statistically different from the ITG.

patients with radiographically confirmed macrocystic lesions had the greatest likelihood of clinical success and in those patients

with mixed lesions, clinical success was also present.

Success was defined as complete or substantial response.

data prior to dosing with OK-432.

After dosing, the clinical success rate was 66%, which was not statistically different from the ITG.

were analyzed by lesion type across all treatment groups.

There are approximately 65,000 incident cases of NMIBC in the United

States every year, and based upon currently available data we believe that approximately 45% (approximately 30,000) are made up of high-grade

tumor types that are considered higher risk, and therefore candidates for immunotherapies, such as TARA-002.

In addition, NMIBC has one

of the highest rates of recurrence with the five-year rate estimated at up to 70%.

Treatment for NMIBC is typically

targeted to reduce unresectable persistence, recurrence after resection and to prevent disease progression to muscle-invasive bladder

The initial treatment for NMIBC includes cystoscopy and complete transurethral resection of the bladder tumor, or TURBT, for papillary

Ta or T1, or biopsy for CIS.

A single postoperative instillation of intravesical chemotherapy is recommended in patients with low risk

of progression, and for patients with intermediate and high-risk disease, a longer course of intravesical therapy is administered.

most efficacious intravesical agent to date has been BCG, a live attenuated form of Mycobacterium bovis .

BCG has been the subject

of multiple supply shortages in the US in the past decade due to the inability to meet demand to treat the large population of patients

There has been a significant increase in bladder cancer recurrence and progression with an escalated number of patients who

require cystectomy.

As such, with the current BCG shortage and limited effective alternate therapies or dosing strategies, there continues

to be a significant unmet need for treatment options for patients with NMIBC.

Clinical Development

We have an open investigational new drug application, or IND, for LMs

with the Vaccines and Related Products Division of the FDA, or Vaccines Division.

In October 2023, we initiated the STARBORN-1 trial,

a Phase 2 single arm, open-label clinical trial to evaluate the safety and efficacy of TARA-002 in pediatric patients with macrocystic

and mixed-cystic LMs.

The trial design includes a safety lead-in phase followed by an expansion phase.

Safety Profile on OK-432, predecessor therapy to TARA-002

most common adverse events with treatment with OK-432 were local injection site reactions, fever, fatigue, and decreased appetite, with

resolution within two weeks.

Treatment emergent serious adverse events or SAEs, (treatment emergent SAEs are defined as any SAE occurring

or worsening on or after the first dose of study drug and within 35 days after the last dose of study drug) associated with OK-432 treatment

were reported in 4.1% of patients, with the most severe events being airway obstruction and facial paralysis due to massive swelling

post-injection that required tracheostomy and hospitalization.

Both of these events were reported as resolved.

safety findings from the sponsor-conducted retrospective analysis are consistent with the original analysis reported in Smith et al.

2009, and with safety data in published studies in approximately 865 patients with LMs after treatment with OK-432.

Preclinical Development on OK-432, predecessor therapy to TARA-002

comprehensive preclinical development program for OK-432, including in vitro and in vivo pharmacology and toxicology studies,

was conducted by Chugai Pharmaceutical to support the filing of a NDA with the Japan Pharmaceuticals and Medical Devices Agency.

these studies may help inform the design of a development plan for TARA-002 in LMs.

We conducted a Phase 1 open-label clinical trial to evaluate TARA-002

in treatment-naïve and treatment-experienced NMIBC patients with CIS and Ta, known as the ADVANCED-1 trial.

In the initial dose escalation

phase of the clinical trial, patients received six weekly intravesical doses of TARA-002, evaluating the 10KE, 20KE and 40KE doses.

primary objective of the clinical trial was to evaluate the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002,

with the goal of establishing a recommended Phase 2 dose.

Data from the ADVANCED-1 trial suggested that intravesical TARA-002

was generally well tolerated at the three dose levels evaluated in the initial phase of the clinical trial (10KE, 20KE, and 40KE), and

no dose limiting toxicities were observed.

A maximum tolerated dose was not determined, and we selected the 40KE dose for use in subsequent

clinical trials.

The majority of reported adverse events were Grades 1 and 2 across all dose levels, and TEAEs, as assessed by study investigators,

were in line with typical responses to bacterial immunopotentiation and included fatigue, headache, fever and chills.

The most common

urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning, incomplete emptying and bladder spasm.

irritations resolved soon after administration, or in a few hours to a few days.

A total of nine patients were enrolled in the dose escalation

portion of the study through the 40KE dose.

Of those, three patients with CIS, one of whom was a heavily pre-treated BCG-Unresponsive

patient, achieved a complete response, or CR, at the 20KE dose, and tumor regression was observed in the other two patients.

six patients with high-grade, non-invasive papillary, or HGTa, tumors showed five of six patients with high-grade recurrence free survival,

or HGRFS, at week 12.

The patient who did not achieve HGRFS was dosed at 10KE, the lowest dose of TARA-002 offered in the clinical trial.

An exploratory cohort of dose escalation at the 80KE was also completed demonstrating similar tolerability to the 40KE dose.

Additionally, we completed

an open-label expansion clinical trial, or ADVANCED-1EXP, evaluating intravesical TARA-002 at the 40KE dose in CIS patients, including

BCG-Naïve, BCG-Unresponsive, and BCG-Experienced patients and are conducting an open-label Phase 2 clinical trial, or ADVANCED-2,

assessing intravesical TARA-002 in NMIBC patients with CIS (± Ta/T1) who are BCG-Naïve (n=27) and BCG-Unresponsive (n≈100).

In April 2024, we announced

positive data from three-month evaluable NMIBC patients with CIS pooled across our clinical studies, including ADVANCED-1 Phase 1a, ADVANCED-1

EXP Phase 1b and ADVANCED-2 Phase 2 trials of TARA-002 in patients with high-risk NMIBC, including BCG-Unresponsive, BCG-Experienced and

BCG-Naïve patients.

The overall three-month CR rate prior to reinduction for the 16 evaluable patients was 38%, with a CR rate of

63% in CIS-only patients and 13% in patients with CIS +Ta/T1 (T1 is defined as carcinoma invading the lamina propria).

A 43% CR rate was

observed in BCG-Unresponsive/Experienced patients.

TARA-002 demonstrated a favorable safety and tolerability profile.

The majority of

reported adverse events were Grades 1 and 2 across all dose levels, and there were no Grade 3 or higher TEAEs.

TEAEs as assessed by study

investigators, were in line with typical responses to bacterial immunopotentiation, and included fatigue, headache, fever and chills.

The most common urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning, incomplete emptying and bladder

Most bladder irritations resolved in a few hours to a few days.

Additional details regarding the data, which support the potential

for TARA-002 in treating high risk patients can be found in the following table:

Three Month Evaluable Patients

BCG-Unresponsive/Experienced

By Stage of Disease at Baseline

Phase 2 Naïve

Data cutoff date:

March 19, 2024

In December 2024, we presented

interim results from our ongoing Phase 2 ADVANCED-2 clinical trial of TARA-002 in patients with NMIBC.

The dataset included 20 patients

who were evaluable at three months, 18 patients who were evaluable at six months and three patients who were evaluable at nine months

with a data cutoff of November 19, 2024.

The CR rate across BCG exposures was 72% (13/18) at six months and 70% (14/20) at any time, with

100% (9/9) of patients maintaining a CR from three months to six months.

In addition, two of three patients maintained a CR at nine months.

In the pivotal cohort of the ADVANCED-2 trial in BCG-Unresponsive patients, the CR rate was 100% (4/4) at six-months and 80% (4/5) at

In the proof-of concept cohort of BCG-Naïve patients, the CR rate was 64% (9/14) at six months and 67% (10/15) at any time.

BCG-Unresponsive

High-grade CR at any time

High-grade CR at timepoint

High-grade CR at Month 6 by Baseline Diagnosis

Data cutoff date:

November 19, 2024

The BCG-Unresponsive cohort has been designed to be registrational

and aligned with the FDA’s August 2024 Draft Guidance BCG-Unresponsive Nonmuscle Invasive Bladder Cancer:

Developing Drugs and Biological

Products for Treatment.

Clinical trial subjects receive an induction course of six weekly intravesical instillations, and following mandatory

biopsy at three months, receive either a reinduction course of six weekly intravesical instillations of TARA-002, or the first maintenance

course of three weekly installations every three months, for an additional 12 months.

We anticipate sharing interim 12-month data from

the ADVANCED-2 trial by mid-2025 and results from a interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients

by the end of 2025.

We intend to discuss with the FDA a protocol for a registrational trial evaluating TARA-002 in BCG-Naïve patients,

and expect to provide an update on the design of this clinical trial following regulatory alignment.

Non-clinical Development

We continue to conduct non-clinical

studies on TARA-002 to better characterize the mechanism of action to help us understand how TARA-002 may perform in potential combinations

with other agents used to treat NMIBC.

We have completed non-clinical studies comparing TARA-002 to BCG.

Mechanistically, TARA-002 and

BCG are similar in that they are both intravesically administered broad-spectrum immune potentiators that drive a TH-1 pro-inflammatory

response and have a preference to M1 polarization.

We found several important differences when we compared the two agents in non-clinical

studies that we believe make TARA-002 a potentially compelling new therapy.

We found that TARA-002 is a NOD2/TLR 2 agonist (NOD2 is defined

as Nucleotide-binding oligomerization domain 2;

TLR 2 is defined as toll-like receptor 2) and BCG is a toll-like receptor 4, or TLR4,

When we compared TARA-002 directly to BCG, in a cytotoxicity assay, we found that TARA-002 resulted in significantly stronger

tumor cell killing compared to BCG.

We also found that TARA-002 resulted in significantly higher upregulation of key pro-inflammatory

cytokines and chemokines, including tumor necrosis factor alpha, or TNF-α, and interferon gamma, or interferon-γ.

observed that TARA-002 meaningfully down-regulated Interleukin-8, or IL-8, which at prolonged elevations is thought to increase risk for

tumor recurrence in bladder cancer after BCG therapy.

The approved indications

for OK-432 in Japan are based on systemic administration of the drug.

There is a significant existing safety database with this route

of administration for OK-432 in Japan.

In addition, we have completed subcutaneous systemic toxicology studies of TARA-002 and we intend

to initiate a proof-of-concept study exploring systemic administration of TARA-002 in 2025.

Regulatory Interactions

July 2020, the FDA granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs.

The FDA grants Rare Pediatric Disease

designation for serious diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the United

Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval of a NDA or

BLA for a product for the prevention or treatment of a rare pediatric disease may be eligible for a voucher, which can be redeemed to

obtain priority review for any subsequent marketing application or may be sold or transferred.

The robust dataset for OK-432 in LMs has informed our development of

At the FDA’s request, we submitted the full CSR of the randomized Phase 2 clinical trial of OK-432 in LMs led by the University

of Iowa to our open IND with the Vaccines Division.

We incorporated feedback from the Vaccines Division on the protocol for our ongoing

Phase 2 clinical trial evaluating TARA-002 in LMs.

In October 2021, we announced that the Office of Tissues and Advanced

Therapies Division, now referred to as the Office of Therapeutic Products, of the FDA’s Center for Biologics Evaluation and Research,

or CBER, cleared our IND application for TARA-002 in NMIBC.

We have had ongoing dialogue with the FDA to align on the potential clinical

trial design of a registrational trial of TARA-002 for the treatment of BCG-Naïve NMIBC, as well as a combination trial with TARA-002

and a checkpoint inhibitor for the treatment of NMIBC and the design of a clinical trial evaluating the systemic priming dose of TARA-002

in BCG-Naïve and BCG-Exposed NMIBC.

In addition, we have had interactions with regulatory authorities

in six countries outside the U.S.

in order to open clinical trial sites for the ADVANCED-2 trial in these international locations.

Manufacturing

We manufacture TARA-002 using an equivalent, but modernized, proprietary

manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting with a master cell line propagated by us but utilizing

the same genetically distinct strain of Streptococcus pyogenes (A group, type 3) Su strain as OK-432.

We have contracted a cGMP-compliant

CDMO, to manufacture TARA-002.

Choline Chloride for PN Patients

Choline Chloride is an IV substrate therapy in development for patients receiving PN.

Choline is a known important substrate for phospholipids, a source

of methyl groups needed for many steps in metabolism and plays important roles in modulating gene expression, cell membrane signaling,

lipid transport and metabolism, liver health, brain development and neurotransmission, muscle function and bone health.

The only way to

reliably replenish choline is through exogenous consumption.

Patients receiving PN cannot sufficiently absorb adequate levels of choline

and available PN components do not contain sufficient amounts of choline to correct this deficit.

The use of choline for PN patients is

included in key professional medical society recommendations, including the American Society for Parenteral and Enteral Nutrition, or

IV Choline Chloride has been granted Orphan Drug Designation, or ODD, by the FDA for the prevention of choline deficiency in PN

have entered into a license agreement with Dr.

Alan Buchman for exclusive rights to the IND, ODD and other regulatory assets related

to IV Choline Chloride, as well as exclusive rights to the data from previously conducted Phase 1 and Phase 2 clinical trials led by

results of Dr.

Buchman’s randomized, controlled, Phase 2 clinical trial demonstrated that treatment with IV Choline Chloride resulted

in normalization of plasma-free choline concentrations, improvement of hepatic steatosis, and statistically significant improvement in

cholestasis in patients dependent on PN.

manufactured using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai

Pharmaceutical.

We propagated a master cell bank using the same master cell line of the genetically distinct strain of Streptococcus

pyogenes (A group, type 3) Su strain as OK-432.

The bacteria is rendered inactive during the manufacturing process, consistent with

the process used for OK-432.

We have contracted a cGMP compliant CDMO to manufacture TARA-002.

The manufacturing facility

of our CDMO for TARA-002 currently has a twenty million vial annual capacity with the ability to expand capacity by five hundred percent.

With TARA-002’s efficient two-hour doubling time, we have an approximate two-week batch completion rate and manufactured 47 successful

consecutive batches by the end of 2024.

The facility which manufactures TARA-002 has been inspected by the FDA and at the most recent

inspection no Form 483s were issued.

IV Choline Chloride for PS Patients

IV Choline Chloride is an

IV substrate therapy in development for patients receiving PS.

Choline is a known important

substrate for phospholipids, a source of methyl groups needed for many steps in metabolism and plays important roles in modulating gene

expression, cell membrane signaling, lipid transport, metabolism, liver health, brain development, neurotransmission, muscle function

and bone health.

The only way to reliably replenish choline is through exogenous consumption.

Patients receiving PS cannot sufficiently

absorb adequate levels of choline and available PS components do not contain sufficient amounts of choline to correct this deficit.

use of choline for PS patients is included in key professional medical society recommendations, including ASPEN.

IV Choline Chloride has

been granted Orphan Drug Designation, or ODD, by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term

We have entered into a license

agreement with Dr.

Alan Buchman for exclusive rights to the IND, ODD and other regulatory assets related to IV Choline Chloride, as well

as exclusive rights to the data from previously conducted Phase 1 and Phase 2 clinical trials led by Dr.

The results of Dr.

randomized, controlled, Phase 2 clinical trial demonstrated that treatment with IV Choline Chloride resulted in normalization of plasma-free

choline concentrations, improvement of hepatic steatosis, and statistically significant improvement in cholestasis in patients dependent

Disease Overview

PN is a medication used to manage and treat malnourishment and is

indicated when there is impaired gastrointestinal function and contraindications to enteral nutrition.

Currently, PN typically consists

of carbohydrate (typically derived from dextrose), fat (lipid emulsion with essential fatty acids), protein (in the form of a balanced

free amino acid solution), electrolytes, trace elements, and most vitamins and essential nutrients known to be required by the human

body, with the notable exception of choline.

The American Society for Parenteral and Enteral Nutrition and the Academy of Nutrition and

Dietetics’ Dietitians in Nutrition Support both recommend that choline be required in PN products (Vanek et al., 2012);

there are currently no FDA approved intravenous choline chloride products.

Humans can produce choline endogenously in the liver, but

the amount that the body naturally synthesizes is not sufficient to meet human needs, making it an essential nutrient.

As a result, humans

must obtain choline from their diets.

The development of IV Choline Chloride is intended to restore circulating choline to physiologic

concentrations in patients who are dependent on PN.

Buchman’s Phase 2 randomized, double-blind, controlled 24-week clinical trial, patients (n=15) receiving nightly PN for >

85% of their nutritional needs (for at least 12 weeks prior to entry) were randomized to receive via IV infusion (10-12 hours) their

usual PN with placebo (n = 8), or PN to which 2g IV Choline Chloride was added (n = 7).

the IV Choline Chloride group, mean choline levels were within or greater than the estimated normal range (i.e., 6.7 to 26.9 nmol/mL)

throughout the 24-week trial and quickly returned to baseline levels when treatment was discontinued.

Preclinical Studies Conducted by us for IV Choline Chloride

PN typically consists of carbohydrate (typically derived from

dextrose), fat (lipid emulsion with essential fatty acids), protein (in the form of a balanced free amino acid solution), electrolytes,

trace elements, and most vitamins and essential nutrients known to be required by the human body, with the notable exception of choline.

PS is a medical treatment, representing PN plus fluids and is used to manage and treat malnourishment and is indicated when there is impaired

gastrointestinal function and contraindications to enteral nutrition.

The American Society for Parenteral and Enteral Nutrition and the

Academy of Nutrition and Dietetics’ Dietitians in Nutrition Support both recommend that choline be required in PN products (Vanek

et al., 2012);

however, there are currently no FDA-approved intravenous choline chloride products.

Humans can produce choline endogenously

in the liver, but the amount that the body naturally synthesizes is not sufficient to meet human needs, making it an essential nutrient.

As a result, humans must obtain choline from their diets.

The development of IV Choline Chloride is intended to provide a source of choline

when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Clinical Development

Buchman’s Phase

2 randomized, double-blind, controlled 24-week clinical trial, patients (n=15) receiving nightly PN for > 85% of their nutritional

needs (for at least 12 weeks prior to entry) were randomized to receive via IV infusion (10-12 hours) their usual PN with placebo (n =

8), or PN to which 2g IV Choline Chloride was added (n = 7).

In the IV Choline Chloride

group, mean choline levels were within or greater than the estimated normal range (i.e., 6.7 to 26.9 nmol/mL) throughout the 24-week trial

and quickly returned to baseline levels when treatment was discontinued.

In April 2024, we announced

alignment with the FDA on a registrational path forward for IV Choline Chloride.

Previously, we had been pursuing an indication in intestinal

failure-associated liver disease, or IFALD, and following feedback from the FDA, are pursuing a broader indication as a source of choline

when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Feedback from the FDA on our IV Choline Chloride program

indicated that a single study with an endpoint of restoring choline levels in PS patients could serve as the basis for a regulatory submission

for IV Choline Chloride.

We plan to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients

on long-term PS and intend to initiate THRIVE-3, a registrational Phase 3 clinical trial in the first half of 2025.

THRIVE-3 is a seamless

Phase 2b/3 trial with a dose confirmation portion (n=24) followed by a double-blinded, randomized, placebo-controlled portion to assess

the efficacy and safety of IV Choline Chloride over 24 weeks in adolescents and adults on long-term PS when oral or enteral nutrition

is not possible, insufficient, or contraindicated (n=100).

The primary endpoint of the clinical trial is a pharmacokinetic, or PK, endpoint

measuring the change from baseline in plasma choline concentration.

We also plan to include a number of secondary endpoints related to

liver, bone, and memory.

The FDA has also granted IV Choline Chloride Fast Track Designation as a source of choline when oral or enteral

nutrition is not possible, insufficient, or contraindicated.

In September 2024, we presented

the results of THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients

dependent on PS in the U.S., U.K, and Europe at the ESPEN Congress.

The study found that 78% of patients who are dependent on PS were

choline deficient, and that 63% of choline deficient participants had liver dysfunction, including steatosis, cholestasis and hepatobiliary

injury, underscoring the need for IV Choline supplementation in this patient population.

Preclinical Development

Preclinical Studies

Conducted by us for IV Choline Chloride

Brief Description

15 unchanged sentences

Assessment of Choline as a Substrate of Human BSEP Mediated Transport

Nonclinical pharmacology studies

Non-clinical pharmacology studies

Non-GLP Pilot Single Dose, Escalating Dose Tolerance Study of Choline by Intravenous Infusion in Male Beagle Dogs

1 unchanged sentence

GLP Combined Single-dose IV Neurobehavioral and Respiratory Study

We continue to engage with the FDA and plan to use both regulatory

feedback and results from the prevalence study to inform next steps for the IV Choline Chloride development program.

Regulatory Interactions

IV Choline Chloride has been

granted Orphan Drug Designation, or ODD, by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term

In April 2024, we announced

alignment with the FDA on a registrational path forward for IV Choline Chloride.

In October 2024, the FDA

granted Fast Track Designation to IV Choline Chloride as a source of choline when oral or enteral nutrition is not possible, insufficient,

or contraindicated.

Manufacturing

We have contracted a CDMO,

to manufacture IV Choline Chloride.

Our end-to-end manufacturing of IV Choline Chloride is conducted in the United States by a cGMP-compliant

Collaborations

and License Agreements

On June 17, 2019, we entered into an agreement, or the Chugai Agreement,

with Chugai Pharmaceutical, a company organized and existing under the laws of Japan.

Chugai Pharmaceutical has developed and commercialized

a therapeutic product, OK-432, or Existing Product, in Japan and Taiwan, or the Chugai Territory, and owns and controls certain materials

and documents related to the Existing Product, or the Chugai Materials.

Pursuant to the Chugai Agreement, Chugai Pharmaceutical has provided

us with certain materials and documents relating to the Existing Product and has provided certain technical services to us for our development

and commercialization.

This pertains to territories other than the Chugai Territory, or the Protara Territory, of a new therapeutic product,

or the New Product or TARA-002, comparable to the Existing Product.

Under the Chugai Agreement, Chugai Pharmaceutical will exclusively

provide the Existing Product and Chugai Materials to us and will not provide the Existing Product or Chugai Materials to any third parties

during the Chugai Service Period, other than for medical, compassionate use and/or non-commercial research purposes.

Additionally, beginning

on the effective date of the Chugai Agreement and ending on the fifth anniversary of such date or upon the termination of the Chugai Agreement,

whichever comes earlier, Chugai Pharmaceutical will not provide Chugai Materials or technical support to any third-party for the purpose

of development and commercialization in the Protara Territory of a therapeutic product comparable to the Existing Product.

We are responsible,

at our sole cost and expense, for the development and commercialization of the New Product in the Protara Territory.

Our end-to-end manufacturing

of IV Choline Chloride is conducted in the United States by a cGMP compliant CDMO.

The facility which manufactures IV Choline Chloride

has been inspected by the FDA and at the most recent inspection no Form 483s were issued.

TARA-002 in LMs

Disease Overview

The International Society

for the Study of Vascular Anomalies classifies LMs as either macrocystic, microcystic, or mixed-cystic.

Macrocystic and microcystic LMs

are differentiated by the size of the fluid-containing portion of the malformation.

Macrocystic LMs are characteristically large, fluid-filled

cysts with a thin endothelial lining.

Macrocystic LMs are composed of cysts greater than 2 cubic centimeters in size and present as a

soft, fluid-filled swelling beneath normal or slightly discolored skin.

Macrocystic LMs are usually located in the antero-lateral cervical

region of the neck;

however, it is possible for this type of LM to originate in other areas of the body.

In contrast, microcystic LMs

have very limited internal space with a thick irregular endothelial lining.

Microcystic LMs are comprised of cysts less than 2 cubic centimeters

in size and are often composed of micro-lymphatic channels that integrate and infiltrate normal soft tissue.

Microcystic LMs can involve

both superficial and deep aspects including muscle and bone.

Microcystic LMs can thicken or swell causing enlargement of surrounding soft

tissue and bones and can be found on any area of the skin or mucous membrane.

Mixed-cystic LMs are comprised of varying degrees of both

macrocystic and microcystic LMs.

While the exact prevalence

of LMs is not known, in the United States, the condition is thought to be present in approximately one in every 4,000 live births and

we believe there are approximately 1,400-1,800 LM cases per year.

We are not aware of any approved

pharmacotherapies for LMs, except in Japan and Taiwan where OK-432 is approved.

In Japan, for example, OK-432 has been the standard of

care for LMs for over 25 years.

Treatment of LMs varies depending

on the symptoms and complications that present themselves.

The standard of care outside Japan for the treatment of LMs is either a partial

or complete surgical excision of the cysts.

While surgery is the standard approach to the treatment of LMs in the head and neck, the region

is a difficult area to operate on because of the large number of important anatomical structures in the area.

Major venous and arterial

trunks travel through the neck, as do important nerves.

Surgery on such malformations frequently results in high rates of recurrence and

complications including life-long chronic conditions, such as damage to nerves and other important structures of the head and neck.

Clinical Development

Historical Data on OK-432, predecessor therapy

When TARA-002 is administered,

it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade.

monocytes, and lymphocytes infiltrate the abnormal cells and various cytokines, including interleukins IL-2, IL-6, IL-10, IL-12, interferon-γ,

and TNF-α are secreted by immune cells to induce a strong inflammatory reaction and destroy the abnormal cells.

In concert, these

immune activities induce a strong local inflammatory reaction in the cyst wall, resulting in fluid drainage, shrinkage and fibrotic adhesion

A randomized, Phase 2 clinical trial led by the University of Iowa

studied the use of OK-432 in patients with LM from 1998 to 2005.

Most eligible subjects were between 6 months and 18 years of age with

macrocystic or mixed-cystic LMs (with ≥ 50% macrocytic disease) of the head and/or neck.

There were three treatment groups:

treatment, or ITG, delayed treatment, or DTG, and open label treatment group.

The ITG received treatment with OK-432 upon diagnosis.

DTG received OK-432 treatment following a six-month observation period;

the cross-over design was intended to investigate spontaneous

The open-label treatment group included infants younger than six months of age, adults older than 18 years of age, patients

with LMs involving sites other than the head and neck (such as the axilla, thorax, and extremities), and patients treated on an emergent

The open label treatment group were treated immediately with OK-432.

Response to therapy was measured by quantitating change in

Clinical success was defined as a complete (90% to 100%) or substantial (60% to 89%) response to treatment based on radiographically

confirmed shrinkage in lesions.

The study results were based on a retrospective analysis of source

verified data that included the full dataset of subjects enrolled in the Phase 2 randomized clinical trial between January 1998 and August

2005, including data in the published study (Smith et al.

2009) that included subjects enrolled between January 1998 and November 2004.

Overall, 310 subjects were

enrolled with intent to treat:

246 subjects were randomized to the immediate (ITG, N=171) and delayed (DTG, N=75) treatment groups;

subjects were nonrandomized and assigned to the open-label group.

Analysis of the primary efficacy endpoint (N=150) demonstrated clinical

success (complete and/or substantial response) in 69% of patients in the ITG 6 months after enrollment, while 7.5% of patients in the

DTG experienced spontaneous regression of a LM during this time interval (p < 0.0001)).

When the results were analyzed by lesion type

across all treatment groups, a successful outcome was observed in 84% and 60% of patients with macrocystic and mixed-cystic LM, respectively.

None of the patients with microcystic LM demonstrated clinical success with OK-432 therapy.

The results of the retrospective analysis

were consistent with the results observed in the original analysis (Smith et al.

69% of patients

in the immediate treatment group had a complete or substantial response to OK-432, meeting the primary endpoint, while 7.5% of patients

in the delayed treatment group had a complete or substantial response after six months of observation and before treatment.

Success was defined as complete or substantial response.

* Results were analyzed by lesion type across all treatment groups

patients with radiographically

confirmed macrocystic lesions had the greatest likelihood of clinical success and in those patients with mixed lesions, clinical success

was also present.

Success was defined as complete or substantial response.

data prior to dosing with OK-432.

After dosing, the clinical success rate was 66%, which was not statistically different from the ITG.

Results were analyzed by lesion type across all treatment groups.

TARA-002 Clinical Development

We have an open investigational IND for LMs with the Vaccines

In October 2023, we initiated the STARBORN-1 trial, a Phase 2 single arm, open-label clinical trial to evaluate the safety and

efficacy of TARA-002 in approximately 30 pediatric patients ages 6 months to less than 18 years old with macrocystic and mixed-cystic

The clinical trial design includes a safety lead-in phase followed by an expansion phase.

The primary endpoint of the clinical trial

is the proportion of participants with macrocystic and mixed cystic LMs who demonstrate clinical success, defined as having either a complete

response (90% to 100% reduction from baseline in total LM volume) or substantial response (60% to less than 90% reduction in total LM

volume) as measured by axial imaging.

Of three patients treated in the first cohort, which enrolled individuals six years to less than

18 years of age, two patients treated with TARA-002 achieved a complete response after receiving one dose of TARA-002;

the responses were

seen in a patient with a macrocystic lymphatic malformation and a patient with a maxillofacial cyst called a ranula.

Historical Safety Profile on OK-432, predecessor

therapy to TARA-002

The most common adverse events with treatment with OK-432 were local

injection site reactions, fever, fatigue, and decreased appetite, with resolution within two weeks.

Treatment emergent serious adverse

events, or SAEs, (treatment emergent SAEs are defined as any SAE occurring or worsening on or after the first dose of study drug and within

35 days after the last dose of study drug) associated with OK-432 treatment were reported in 4.1% of patients, with the most severe events

being airway obstruction and facial paralysis due to massive swelling post-injection that required tracheostomy and hospitalization.

of these events were reported as resolved.

The safety findings from

the sponsor-conducted retrospective analysis are consistent with the original analysis reported in Smith et al.

2009, and with safety

data in published studies in approximately 865 patients with LMs after treatment with OK-432.

Historical Preclinical Development on

OK-432, predecessor therapy to TARA-002

A comprehensive preclinical development program for OK-432, including

in vitro and in vivo pharmacology and toxicology studies, was conducted by Chugai Pharmaceutical to support the filing and

approval of an NDA with the Japan Pharmaceuticals and Medical Devices Agency.

We believe these studies may help inform the design of a

development plan for TARA-002 in LMs.

In addition, there is a significant body of literature exploring the use of OK-432 in other

maxillofacial cysts demonstrating strong potential for TARA-002 to be explored in the treatment of these cysts as well.

Regulatory Interactions

In July 2020, the FDA granted Rare Pediatric Disease Designation for

TARA-002 for the treatment of LMs.

The FDA grants Rare Pediatric Disease Designation for serious diseases that primarily affect children

ages 18 years or younger and fewer than 200,000 persons in the United States.

Under the FDA’s Rare Pediatric Disease Priority Review

Voucher program, a sponsor who receives an approval of an NDA or BLA for a product for the prevention or treatment of a rare pediatric

disease may be eligible for a voucher, which can be redeemed to obtain priority review for any subsequent marketing application or may

be sold or transferred prior to such redemption.

Currently in order to obtain a voucher, the NDA or BLA for a product candidate that was

granted Rare Disease Designation before December 20, 2024 must be approved by September 30, 2026, unless the program is extended by Congress.

In May 2022 the European Commission granted Orphan Drug Designation

to TARA-002 for the treatment of LMs.

Manufacturing

manufactured using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai

Pharmaceutical.

We propagated a master cell bank using the same master cell line of the genetically distinct strain of Streptococcus

pyogenes (A group, type 3) Su strain as OK-432.

The bacteria is rendered inactive during the manufacturing process, consistent with

the process used for OK-432.

The facility which manufactures TARA-002 has been inspected by the FDA and at the most recent

inspection no Form 483s were issued.

Collaborations and License Agreements

Chugai Agreement

On June 17, 2019, we entered

into an agreement, or the Chugai Agreement, with Chugai Pharmaceutical, a company organized and existing under the laws of Japan.

Pharmaceutical has developed and commercialized a therapeutic product, OK-432, or Existing Product, in Japan and Taiwan, or the Chugai

Territory, and owns and controls certain materials and documents related to the Existing Product, or the Chugai Materials.

the Chugai Agreement, Chugai Pharmaceutical has provided us with certain materials and documents relating to the Existing Product and

has provided certain technical services to us for our development and commercialization.

This pertains to territories other than the Chugai

Territory, or the Protara Territory, of a new therapeutic product, or the New Product or TARA-002, comparable to the Existing Product.

Under the Chugai Agreement, Chugai Pharmaceutical will exclusively provide the Existing Product and Chugai Materials to us and will not

provide the Existing Product or Chugai Materials to any third parties during the Chugai Service Period, other than for medical, compassionate

use and/or non-commercial research purposes.

Additionally, beginning on the effective date of the Chugai Agreement and ending on the fifth

anniversary of such date or upon the termination of the Chugai Agreement, whichever comes earlier, Chugai Pharmaceutical will not provide

Chugai Materials or technical support to any third-party for the purpose of development and commercialization in the Protara Territory

of a therapeutic product comparable to the Existing Product.

We are responsible, at our sole cost and expense, for the development and

commercialization of the New Product in the Protara Territory.

On July 14, 2020, we and Chugai Pharmaceutical entered into an amendment

of the Chugai Agreement, or the Chugai Amendment, with an effective date as of June 30, 2020.

The Chugai Amendment extended the date through

which Chugai will exclusively provide the Existing Product and materials to us from June 30, 2020 to June 30, 2021, extended the date

through which Chugai will not provide materials or technical support to any third-party for the purpose of development and commercialization

of the Chugai Agreement, or the Chugai Pharmaceutical Amendment, with an effective date as of June 30, 2020.

The Chugai Amendment extended

the date through which Chugai will exclusively provide the Existing Product and materials to us from June 30, 2020 to June 30, 2021, extended

the date through which Chugai will not provide materials or technical support to any third-party for the purpose of development and commercialization

in a given area from the fifth anniversary to the eleventh anniversary of the original effective date (extended to June 17, 2030), and

1 unchanged sentence

The Chugai Amendment also provides that, in addition

to the designated fee payable upon the initial indication approval in the Chugai Agreement described below, we will pay Chugai a designated

fee in the low, single digit millions for each additional indication approval.

consideration for Chugai Pharmaceutical’s performance under the Chugai Agreement, we agreed to pay Chugai Pharmaceutical a payment

in the low, single-digit millions, which will be made in two installments with an initial payment made in July 2020, and the remaining

majority of the total amount will be payable upon FDA approval of the New Product.

We granted Chugai Pharmaceutical a right of first refusal on terms

to be negotiated between the parties for a license related to the New Product-relevant information, data and documentation and inventions

to develop and commercialize the New Product in the Chugai Territory.

We will be responsible for manufacturing and supplying, or causing

our CDMO to manufacture and supply, the New Product to Chugai Pharmaceutical.

Chugai Agreement will remain in full force and effect until the first anniversary of the date of FDA approval of the New Product, unless

terminated sooner, or the Chugai Term.

Following the Chugai Service Period and during the Chugai Term, Chugai Pharmaceutical may terminate

the Chugai Agreement, in whole or in part, without cause, by providing us 90 days prior written notice.

Following such termination, we

would maintain exclusive access to Chugai Materials, subject to the termination clauses outlined below.

We may terminate the Chugai Agreement,

in whole only, by providing Chugai Pharmaceutical 90 days’ prior written notice if (i) we decide to discontinue the New Product

(ii) we decide that the FDA’s requirements for the New Product are not likely to be met;

or (iii) the FDA identifies

a safety issue regarding the New Product.

addition, either party may terminate the Chugai Agreement, in whole or in part, in the event that the other party materially breaches

the Chugai Agreement and fails to cure the breach within 30 days of written notice.

Either party may terminate the Chugai Agreement in

its entirety immediately upon notice to the other party if such other party:

(i) is dissolved or liquidated or takes any corporate action

for such purpose;

(ii) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due;

(iii) files or

has filed against it a petition for voluntary or involuntary bankruptcy or otherwise becomes subject to any proceeding under any domestic

or foreign bankruptcy or insolvency laws;

to the designated fee payable upon the initial indication approval in the Chugai Agreement described below, we will pay Chugai Pharmaceutical

a designated fee in the low, single digit millions for each additional indication approval.

As consideration for Chugai

Pharmaceutical’s performance under the Chugai Agreement, we agreed to pay Chugai Pharmaceutical a payment in the low, single-digit

millions, which will be made in two installments with an initial payment made in July 2020, and the remaining majority of the total amount

will be payable upon FDA approval of the New Product.

We granted Chugai Pharmaceutical

a right of first refusal on terms to be negotiated between the parties for a license related to the New Product-relevant information,

data and documentation and inventions to develop and commercialize the New Product in the Chugai Territory.

We will be responsible for

manufacturing and supplying, or causing our CDMO to manufacture and supply, the New Product to Chugai Pharmaceutical.

The Chugai Agreement will

remain in full force and effect until the first anniversary of the date of FDA approval of the New Product, unless terminated sooner,

or the Chugai Term.

Following the Chugai Service Period and during the Chugai Term, Chugai Pharmaceutical may terminate the Chugai Agreement,

in whole or in part, without cause, by providing us 90 days prior written notice.

Following such termination, we would maintain exclusive

access to Chugai Materials, subject to the termination clauses outlined below.

We may terminate the Chugai Agreement, in whole only, by

providing Chugai Pharmaceutical 90 days’ prior written notice if (i) we decide to discontinue the New Product development;

we decide that the FDA’s requirements for the New Product are not likely to be met;

or (iii) the FDA identifies a safety issue regarding

the New Product.

In addition, either party

may terminate the Chugai Agreement, in whole or in part, in the event that the other party materially breaches the Chugai Agreement and

fails to cure the breach within 30 days of written notice.

Either party may terminate the Chugai Agreement in its entirety immediately

upon notice to the other party if such other party:

(i) is dissolved or liquidated or takes any corporate action for such purpose;

becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due;

(iii) files or has filed against it a

petition for voluntary or involuntary bankruptcy or otherwise becomes subject to any proceeding under any domestic or foreign bankruptcy

or insolvency laws;

(iv) makes or seeks to make a general assignment for the benefit of creditors;

or (v) applies

for or has a receiver, trustee, custodian or similar agent appointed by order of any court to take charge of or sell any material portion

of its property or business.

the event that we undergo a change of control, Chugai Pharmaceutical may terminate the Chugai Agreement upon 90 days’ written notice

to us, absent a written pledge by the new controlling party of its agreement to fulfill and undertake all obligations of ours and to

be bound by the Chugai Agreement.

Research and License Agreement

November 28, 2018, we entered into a sponsored research and license agreement, or the Research Agreement, with The University of Iowa,

or the University, pursuant to which the University will provide access to certain program data related to Chugai Pharmaceutical’s

OK-432 and will assist us in conducting certain clinical studies.

As consideration for the University’s performance under the Research

Agreement, we will pay the University $30,000 per year in funding for the project, taking into consideration the time spent by University

employees required for the Project.

The parties also agree to discuss in good faith potential additional funding required for completion

of the project pursuant to the Research Agreement as applicable and necessary.

In addition, within 45 days of approval of the TARA-002

BLA by the FDA, we will pay a one-time approval milestone to the University, the amount of which depends on the usefulness of the program

data in TARA-002’s BLA filing, and the milestone amount will range from $0 to $1 million.

We will also be responsible for certain

tiered royalties on annual net sales of products for the indication, which royalty rates are in the low single digit percentages.

royalty rates are also subject to a reduction in the event that regulatory authorities determine that the program data is not sufficient

for regulatory approval on its own and additional pediatric efficacy and safety clinical studies are required.

In the event that the

annual net sales surpass certain dollar amount thresholds, we will need to make certain additional milestone payments following the close

of the calendar quarter in which each milestone is reached, with the payments ranging from $62,500 to $125,000.

may terminate the Research Agreement upon 30 days’ prior written notice to the University.

Either party may terminate the project

under the Research Agreement and all commitments and obligations with respect thereto upon 30 days’ prior written notice to the

In the event of any termination of the project under the Research Agreement by the University, (a) the University agrees

to complete certain phases of the project and (b) we will continue to provide annual funding until the completion of the second phase

of the project.

Upon termination of the project by us, the Agreement will terminate and we will reassign to the University the IND for

License Agreement

September 27, 2017, we entered into a choline license agreement, or the Choline Agreement, with Alan L.

Buchman, M.D., pursuant to which

Buchman granted us an exclusive, worldwide, non-transferable license in and to certain licensed orphan designations, a certain licensed

IND, certain existing study data and certain licensed know-how to develop, make, use, sell, offer for sale and import the licensed product

during the term of the Choline Agreement.

We are solely responsible for all fees and expenses under the Choline Agreement, including

all due diligence obligations, regulatory authority fees, attorney fees and consulting fees.

During the term of the Choline Agreement,

Buchman may not work with any third parties on any product competing with the licensed product.

In consideration for the rights and

licenses granted under the Agreement, we made an initial upfront payment of $50,000 to Dr.

milestone and royalty payments may also be payable to Dr.

or (v) applies for or has a receiver,

trustee, custodian or similar agent appointed by order of any court to take charge of or sell any material portion of its property or

In the event that we undergo

a change of control, Chugai Pharmaceutical may terminate the Chugai Agreement upon 90 days’ written notice to us, absent a written

pledge by the new controlling party of its agreement to fulfill and undertake all obligations of ours and to be bound by the Chugai Agreement.

Sponsored Research and License Agreement

On November 28, 2018, we

entered into a sponsored research and license agreement, or the Research Agreement, with The University of Iowa, or the University, pursuant

to which the University will provide access to certain program data related to Chugai Pharmaceutical’s OK-432 and will assist us

in conducting certain clinical studies.

As consideration for the University’s performance under the Research Agreement, we will

pay the University $30,000 per year in funding for the project, taking into consideration the time spent by University employees required

for the Project.

The parties also agree to discuss in good faith potential additional funding required for completion of the project pursuant

to the Research Agreement as applicable and necessary.

In addition, within 45 days of approval of the TARA-002 BLA by the FDA, we will

pay a one-time approval milestone between $0 and $1 million to the University, the amount of which depends on the usefulness of the program

data in TARA-002’s BLA filing.

We will also be responsible for certain tiered royalties on annual net sales of products for the

indication, which royalty rates are in the low single digit percentages.

These royalty rates are also subject to a reduction in the event

that regulatory authorities determine that the program data is not sufficient for regulatory approval on its own and additional pediatric

efficacy and safety clinical studies are required.

In the event that the annual net sales surpass certain dollar amount thresholds, we

will need to make certain additional milestone payments following the close of the calendar quarter in which each milestone is reached,

with the payments ranging from $62,500 to $125,000.

We may terminate the Research Agreement upon 30 days’ prior

written notice to the University.

Either party may terminate the project under the Research Agreement and all commitments and obligations

with respect thereto upon 30 days’ prior written notice to the other party.

In the event of any termination of the project under

the Research Agreement by the University, (a) the University agrees to complete certain phases of the project and (b) we will continue

to provide annual funding until the completion of the second phase of the project.

Upon termination of the project by us, the Agreement

will terminate and we will reassign to the University the IND for LMs.

Choline License Agreement

On September 27, 2017, we entered into a choline license agreement,

or the Choline Agreement, with Alan L.

Buchman, M.D., pursuant to which Dr.

Buchman granted us an exclusive, worldwide, non-transferable

license in and to certain licensed orphan designations, a certain licensed IND, certain existing study data and certain licensed know-how

to develop, make, use, sell, offer for sale and import the licensed product during the term of the Choline Agreement.

We are solely responsible

for all fees and expenses under the Choline Agreement, including all due diligence obligations, regulatory authority fees, attorney fees

and consulting fees.

During the term of the Choline Agreement, Dr.

Buchman may not work with any third parties on any product competing

with the licensed product.

In consideration for the rights and licenses granted under the Choline Agreement, we made an initial upfront

payment of $50,000 to Dr.

Certain milestone and royalty

payments may also be payable to Dr.

Pursuant to the Choline Agreement, we paid Dr.

Buchman $50,000 in

October 2019 because we had not received at least $5 million in working capital from any source or in any manner as of October 15, 2019.

Buchman $50,000 in October 2019 because we

had not received at least $5 million in working capital from any source or in any manner as of October 15, 2019.

We then paid Dr.

Buchman a $550,000 milestone in January 2020 following our receipt of at least $5 million in working capital.

of whether development or commercialization is undertaken by us under the Choline Agreement, commencing in November 2022 and during the

term of the Choline Agreement, we will pay Dr.

a $550,000 milestone in January 2020 following our receipt of at least $5 million in working capital.

Regardless of whether development

or commercialization is undertaken by us under the Choline Agreement, commencing in November 2022 and during the term of the Choline Agreement,

we will pay Dr.

Buchman a minimum annual royalty that ranges from $25,000 to $75,000.

Buchman sales royalties based on aggregate net sales of IV Choline Chloride in each calendar quarter, with the royalty rates

ranging from 5.0% to 10.5% of net sales.

In the event of development or commercialization activity by any sublicensees, we also agreed

Buchman a royalty in the mid-single digit percentage of (i) net cash receipts, after payment of taxes, received by us from

sublicensees for their sales of licensed products and (ii) any other consideration received by us from such sublicensees;

in each case,

We have an obligation to pay Dr.

Buchman sales royalties based on aggregate

net sales of IV Choline Chloride in each calendar quarter, with the tiered royalty rates ranging from 5.0% to 10.5% of net sales.

event of development or commercialization activity by any sublicensees, we also agreed to pay Dr.

Buchman a royalty in the mid-single

digit percentage of (i) net cash receipts, after payment of taxes, received by us from sublicensees for their sales of licensed products

and (ii) any other consideration received by us from such sublicensees;

in each case, including a fair monetary value for any transaction

that is not a bona fide arms-length transaction or that is for consideration other than monetary.

Further, in the event of a sale or transfer

of a priority review voucher regarding the license product, regardless of whether any development or commercialization activity is undertaken

by us or our sublicensees, we agreed to pay Dr.

Buchman a milestone payment representing the mid-single digit percentage of (i) net cash

receipts, after payment of taxes and (ii) any other consideration;

in each case, received by us, our affiliates, or our sublicensees,

including a fair monetary value for any transaction that is not a bona fide arms-length transaction or that is for consideration other

than monetary.

Further, in the event of a sale or transfer of a priority review voucher regarding the license product, regardless of

whether any development or commercialization activity is undertaken by us or our sublicensees, we agreed to pay Dr.

Buchman a milestone

payment representing the mid-single digit percentage of (i) net cash receipts, after payment of taxes and (ii) any other consideration;

in each case, received by us, our affiliates, or our sublicensees, including a fair monetary value for any transaction that is not a

bona fide arms-length transaction or that is for consideration other than monetary.

will also pay Dr.

Buchman up to $775,000 in additional milestone payments upon the achievement of various regulatory approval milestones.

Choline Agreement will remain in full force and effect until the last sale of the licensed product under the Choline Agreement.

we received the FDA’s written minutes from the initial FDA meeting concerning the development of the first licensed product for

one or more of the licensed indications, we paid an additional payment of $100,000 to Dr.

Buchman and elected not terminate the Choline

Agreement at that time.

We will also pay Dr.

up to $775,000 in additional payments upon the achievement of various regulatory approval milestones.

The Choline Agreement will

remain in full force and effect until the last sale of the licensed product under the Choline Agreement.

After we received the FDA’s

written minutes from the initial FDA meeting concerning the development of the first licensed product for one or more of the licensed

indications, we paid an additional payment of $100,000 to Dr.

Buchman and elected to not terminate the Choline Agreement at that time.

The Choline Agreement may be terminated by Dr.

Buchman if, following regulatory approval of a licensed product,

we have not made our first sale of a licensed product within such country within a specified time period.

We may terminate the Choline

Agreement for convenience upon 90 days’ prior written notice to Dr.

Buchman may terminate the Choline Agreement for

non-payment of any payment due that has not been cured.

Either party may terminate the Choline Agreement if the other party is in material

breach and has not cured such breach within 60 days’ notice.

Buchman if, following regulatory approval of a licensed product, we have not made our first

sale of a licensed product within such country within a specified time period.

We may terminate the Choline Agreement for convenience

upon 90 days’ prior written notice to Dr.

Buchman may terminate the Choline Agreement for non-payment of any payment

due that has not been cured.

Either party may terminate the Choline Agreement if the other party is in material breach and has not cured

such breach within 60 days’ notice.

In addition, Dr.

Buchman may terminate the Choline Agreement upon

60 days’ prior written notice if (a) we cease or threaten to cease to carry on our business;

(b) a petition or resolution for the

making of an administration order or for the bankruptcy, winding-up or dissolution of us is presented or passed;

petition in bankruptcy or insolvency;

(d) a receiver or administrator takes possession of our assets or (e) any similar procedure is

commenced against us in the United States.

On December 22, 2017, we entered into a license agreement, or the License

Agreement, with The Feinstein Institute for Medical Research, a not-for-profit corporation organized and existing under the laws of New

York, or the Institute.

Buchman may terminate the Choline Agreement upon 60 days’ prior written

notice if (a) we cease or threaten to cease to carry on our business;

(b) a petition or resolution for the making of an administration

order or for the bankruptcy, winding-up or dissolution of us is presented or passed;

(d) a receiver or administrator takes possession of our assets or (e) any similar procedure is commenced against us in the

United States.

License Agreement

On December 22, 2017, we

entered into a license agreement, or the License Agreement, with The Feinstein Institute for Medical Research, a not-for-profit corporation

organized and existing under the laws of New York, or the Institute.

The Institute owns, by assignment, a U.S.

patent related to the treatment of fatty liver disease in humans.

to the License Agreement, the Institute granted us an exclusive, worldwide license, with the right to grant sublicenses to non-affiliate

third parties, to develop, make, have made, use, sell, offer for sale and import certain products for use in the field of fatty liver

disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous

choline, wherein the fatty liver disease is selected from intestinal failure-associated liver disease, or IFALD, non-alcoholic fatty liver,

non-alcoholic steatohepatitis, or NASH, NASH-associated liver fibrosis, or non-alcoholic cirrhosis.

Notwithstanding the exclusive rights

granted to us, the Institute will retain the right to make, use and practice such patents in its own laboratories solely for non-commercial

scientific purposes and for continued non-commercial research.

consideration for the license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales.

we agreed to pay the Institute a low double digit percentage of net proceeds resulting from agreements entered into within two years

from the effective date of the License Agreement and a mid-single digit percentage of net proceeds resulting from agreements entered

into thereafter.

We also agreed to make certain license maintenance payments of $15,000 beginning on the second anniversary of the effective

date of the License Agreement and continuing upon every anniversary thereafter until the first commercial sale of a licensed product.

Beginning on the first anniversary of the effective date of the License Agreement after the first commercial sale of a licensed product

and every anniversary of the effective date of the License Agreement thereafter, we will pay the Institute $30,000 as a license maintenance

Such license maintenance fees are non-refundable but are creditable against future royalty payments due to the Institute during

the 12-month period following each such anniversary.

agreed to make certain one-time milestone payments in the aggregate amount of $375,000 upon the achievement of certain regulatory approval

milestones, of which $100,000 was paid on January 28, 2020 upon us having consummated certain private placements.

terminated earlier, the License Agreement will expire upon the expiration of the last to expire patent under the License Agreement.

may terminate the License Agreement by giving the Institute 60 days’ prior notice.

Either party may terminate the License Agreement

in the event of a default or breach by the other party that has not been cured within 60 days of such notice.

If we (i) make an assignment

for the benefit of creditors or if proceedings for a voluntary bankruptcy are instituted on our behalf;

(ii) are declared bankrupt or

insolvent or (iii) are convicted of a felony relating to the manufacture, use or sale of the licensed products or a felony relating to

moral turpitude, the Institute may terminate the License Agreement.

intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection

and internationally for our product candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential

indications, and other inventions that are important to our business.

Throughout the development of our product candidates, we will seek

to identify additional means of obtaining patent protection that would potentially enhance commercial success.

We also rely upon trade

secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.

patent positions of biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions.

We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including

the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement

of the patent laws.

In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued,

and its scope can be reinterpreted after issuance.

Consequently, we may not obtain or maintain adequate patent protection for any of

our product candidates.

Any patents that we hold may be challenged, circumvented or invalidated by third parties.

commercial success will also depend in part on not infringing the proprietary rights of third parties.

In addition, we have licensed

rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our products and

It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies,

alter our processes, obtain licenses or cease certain activities.

The expiration of patents or patent applications licensed from third

parties or our breach of any license agreements or failure to obtain a license to proprietary rights that it may require to develop or

commercialize our future technology may have a material adverse impact on it.

If third parties prepare and file patent applications in

the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO,

to determine priority of invention.

For a more comprehensive discussion of the risks related to our intellectual property, please see

“ Risk Factors—Risks Related to Our Intellectual Property.

is a genetically distinct Su strain of Streptococcus pyogenes (group A, type 3).

TARA-002 is produced through a proprietary manufacturing

We believe a significant barrier to entry exists, as we believe only Chugai Pharmaceutical and we have the specific strain and

possess the know-how to manufacture the product.

We anticipate that, if approved by the FDA, TARA-002 will be protected by 12 years of

biologic exclusivity.

Choline Chloride:

respect to IV Choline Chloride, we have acquired an exclusive, worldwide license to U.S.

Patent 8,865,641 B2 from the Feinstein Institute

for Medical Research providing protection in the United States until 2035.

The patent applies to a method of treating a fatty liver disease

in a subject.

In particular, the method comprises administering to the subject an effective amount of a cholinergic pathway stimulating

agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver, alcoholic fatty liver, NASH, alcoholic steatohepatitis,

or ASH, NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis and alcoholic cirrhosis.

in April 2022, the USPTO issued to us Patent No.

US 11,311,503 claiming a sterile aqueous choline salt composition with a term expiring

We would expect to list such patent in the FDA’s Orange Book List of Approved Drug Products with Therapeutic Equivalence

Evaluations if IV Choline Chloride is approved by the FDA.

term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.

In most countries

in which we may file, the patent term is 20 years from the earliest date of filing a non-provisional patent application related to the

patent also may be accorded a patent term adjustment under certain circumstances to compensate for delays in obtaining

the patent from the USPTO.

In some instances, such a patent term adjustment may result in a U.S.

patent term extending beyond 20 years

from the earliest date of filing a non-provisional patent application related to the U.S.

In addition, in the United States,

the term of a U.S.

patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term

restoration as compensation for the patent term lost during the FDA regulatory review process.

The Hatch-Waxman Act permits a patent

term extension of up to five years beyond the expiration of the patent.

The length of the patent term extension is related to the length

of time the drug is under regulatory review.

Patent term extension cannot extend the remaining term of a patent beyond a total of 14

years from the date of product approval and only one patent applicable to an approved drug may be extended.

Similar provisions are available

in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.

In the future, if and when our

products receive FDA approval, we expect to apply for patent term extensions on patents covering certain of those products, when applicable.

also rely on trade secrets relating to product candidates and seek to protect and maintain the confidentiality of proprietary information

to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants,

third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our

trade secrets, including through breaches of such agreements with our employees and consultants.

Thus, we may not be able to meaningfully

protect our trade secrets.

It is our policy to require our employees, consultants, outside scientific partners, sponsored researchers

and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.

agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual

during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except

in specific circumstances.

Our agreements with employees also provide that all inventions conceived by the employee in the course of

employment with us or from the employee’s use of our confidential information are our exclusive property.

patent related to the treatment

of fatty liver disease in humans.

Pursuant to the License Agreement, the Institute granted us an exclusive, worldwide license, with the

right to grant sublicenses to non-affiliate third parties, to develop, make, have made, use, sell, offer for sale and import certain products

for use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical

composition comprising intravenous choline, wherein the fatty liver disease is selected from intestinal failure-associated liver disease,

or IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis, or NASH, NASH-associated liver fibrosis, or non-alcoholic cirrhosis.

Notwithstanding the exclusive rights granted to us, the Institute will retain the right to make, use and practice such patents in its

own laboratories solely for non-commercial scientific purposes and for continued non-commercial research.

As consideration for the

license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales.

In addition, we agreed to pay

the Institute a low double digit percentage of net proceeds resulting from agreements entered into within two years from the effective

date of the License Agreement and a mid-single digit percentage of net proceeds resulting from agreements entered into thereafter.

also agreed to make certain license maintenance payments of $15,000 beginning on the second anniversary of the effective date of the License

Agreement and continuing upon every anniversary thereafter until the first commercial sale of a licensed product.

Beginning on the first

anniversary of the effective date of the License Agreement after the first commercial sale of a licensed product and every anniversary

of the effective date of the License Agreement thereafter, we will pay the Institute $30,000 as a license maintenance fee.

maintenance fees are non-refundable but are creditable against future royalty payments due to the Institute during the 12-month period

following each such anniversary.

We agreed to make certain

one-time milestone payments in the aggregate amount of $375,000 upon the achievement of certain regulatory approval milestones, of which

$100,000 was paid on January 28, 2020 upon us having consummated certain private placements.

Unless terminated earlier,

the License Agreement will expire upon the expiration of the last to expire patent under the License Agreement.

We may terminate the License

Agreement by giving the Institute 60 days’ prior notice.

Either party may terminate the License Agreement in the event of a default

or breach by the other party that has not been cured within 60 days of such notice.

If we (i) make an assignment for the benefit of creditors

or if proceedings for a voluntary bankruptcy are instituted on our behalf;

(ii) are declared bankrupt or insolvent or (iii) are convicted

of a felony relating to the manufacture, use or sale of the licensed products or a felony relating to moral turpitude, the Institute may

terminate the License Agreement.

Intellectual Property

Our intellectual property

is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the U.S.

and internationally

for our product candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions

that are important to our business.

Throughout the development of our product candidates, we will seek to identify additional means of

obtaining patent protection that would potentially enhance commercial success.

We also rely upon trade secrets, know-how, continuing technological

innovation and in-licensing opportunities to develop and maintain our proprietary position.

The patent positions of biotechnology

companies like us are generally uncertain and involve complex legal, scientific and factual questions.

We recognize that the ability to

obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the

novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws.

In addition, the

coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted

after issuance.

Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates.

that we hold may be challenged, circumvented or invalidated by third parties.

Our commercial success will also depend in part on not infringing the

proprietary rights of third parties.

In addition, we have licensed rights under proprietary technologies of third parties to develop,

manufacture and commercialize specific aspects of our products and services.

It is uncertain whether the issuance of any third-party patent

would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities.

The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain

a license to proprietary rights that it may require to develop or commercialize our future technology may have a material adverse impact

If third parties prepare and file patent applications in the United States that also claim technology to which we have rights,

we may have to participate in interference proceedings in the U.S.

Patent and Trademark Office, or USPTO, to determine priority of invention.

For a more comprehensive discussion of the risks related to our intellectual property, please see “ Risk Factors—Risks Related

to Our Intellectual Property.

TARA-002 is a genetically distinct Su strain of Streptococcus

pyogenes (group A, type 3).

TARA-002 is produced through a proprietary manufacturing process, during which the bacteria is inactivated.

We believe a significant barrier to entry exists, as we believe only Chugai Pharmaceutical and we have the specific strain and possess

the know-how to manufacture the product.

We anticipate that, if approved by the FDA, TARA-002 will be protected by 12 years of biologic

IV Choline Chloride:

With respect to IV Choline Chloride, we have acquired an exclusive,

worldwide license to U.S.

Patent 8,865,641 B2 from the Feinstein Institute for Medical Research providing protection in the United States

The patent applies to a method of treating a fatty liver disease in a subject.

In particular, the method comprises administering

to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic

fatty liver, alcoholic fatty liver, or NASH, alcoholic steatohepatitis, or ASH, NASH-associated liver fibrosis, ASH-associated liver fibrosis,

non-alcoholic cirrhosis and alcoholic cirrhosis.

In addition, in 2022, the USPTO issued to us Patent No.

US 11,311,503 claiming a sterile

aqueous choline salt composition with a term expiring in 2041.

We expect to list such patent in the FDA’s Orange Book List of Approved

Drug Products with Therapeutic Equivalence Evaluations if IV Choline Chloride is approved by the FDA.

Further, in 2024, the USPTO issued

to us Patent No.

US 12,083,081 claiming a method of treating choline deficiency with a choline composition, also with a term expiring

The term of individual patents

depends upon the legal term of the patents in the countries in which they are obtained.

In most countries in which we may file, the patent

term is 20 years from the earliest date of filing a non-provisional patent application related to the patent.

patent also may be

accorded a patent term adjustment under certain circumstances to compensate for delays in obtaining the patent from the USPTO.

instances, such a patent term adjustment may result in a U.S.

patent term extending beyond 20 years from the earliest date of filing a

non-provisional patent application related to the U.S.

In addition, in the United States, the term of a U.S.

patent that covers

an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent

term lost during the FDA regulatory review process.

The Hatch-Waxman Act permits a patent term extension of up to five years beyond the

expiration of the patent.

The length of the patent term extension is related to the length of time the drug is under regulatory review.

Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only

one patent applicable to an approved drug may be extended.

Similar provisions are available in Europe and other foreign jurisdictions

to extend the term of a patent that covers an approved drug.

In the future, if and when our products receive FDA approval, we expect to

apply for patent term extensions on patents covering certain of those products, when applicable.

We also rely on trade secrets

relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our

business that are not amenable to, or that we do not consider appropriate for, patent protection.

Although we take steps to protect our

proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently

develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, including through

breaches of such agreements with our employees and consultants.

Thus, we may not be able to meaningfully protect our trade secrets.

is our policy to require our employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute

confidentiality agreements upon the commencement of employment or consulting relationships with us.

These agreements provide that all

confidential information concerning our business or financial affairs developed or made known to the individual during the course of the

individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.

Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the

employee’s use of our confidential information are our exclusive property.

Manufacturing

rely on CDMOs to produce our drug candidates in accordance with cGMP as well as regulations for use in clinical trials and for commercial

The manufacture of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation

requirements and govern all areas of record keeping, production processes and controls, personnel and quality control.

CDMOs that we partner with have the capability to produce clinical supply required for clinical trials, as well as support commercial

scale-up activities for both products.

manufacture TARA-002 using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical,

starting with a master cell line propagated by us but utilizing the same genetically distinct strain of Streptococcus pyogenes (A group,

type 3) Su strain as OK-432.

TARA-002 and IV Choline Chloride are or will be manufactured in the United States.

The starting materials for TARA-002 were provided

to us pursuant to an agreement with Chugai Pharmaceutical.

We rely on CDMOs to produce

our drug candidates in accordance with cGMP as well as regulations for use in clinical trials and for commercial product.

The manufacture

of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern

all areas of record keeping, production processes and controls, personnel and quality control.

The CDMOs that we partner

with have the capability to produce clinical supply required for clinical trials, as well as support commercial scale-up activities for

both TARA-002 and IV Choline Chloride.

TARA-002 is manufactured using an equivalent, but modernized,

proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting with a master cell line propagated by

us but utilizing the same genetically distinct strain of Streptococcus pyogenes (A group, type 3) Su strain, which is inactivated during

the manufacturing process, as OK-432.

Both TARA-002 and IV Choline

Chloride are or will be manufactured in the United States.

The starting materials for TARA-002 were provided to us pursuant to an agreement

with Chugai Pharmaceutical.

The regulatory starting materials for IV Choline Chloride are available commercially.

and Marketing

plan to become a fully-integrated commercial biopharmaceutical company pursuing our mission of supporting and improving the lives of

patients suffering from cancer and rare diseases.

approved by the FDA, we plan to commercialize both of our current product candidates in the United States first and then in other geographies.

As we advance TARA-002 and IV Choline Chloride through our respective clinical development programs, we plan to grow our commercial organization

in support of anticipated product launches.

process for commercialization of new drugs is very competitive, and we could potentially face worldwide competition from other pharmaceutical

companies, biotechnology companies and ultimately generic or biosimilar products.

Our potential competitors may develop or market therapies

that are available sooner, more clinically effective, safer or less expensive than any therapeutic products we develop.

Numerous companies

are engaged in the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are developing.

respect to our lead product candidate, TARA-002, for the treatment of NMIBC and LMs, the active ingredient in TARA-002 is a genetically

distinct strain of Streptococcus pyogenes (group A, type 3) Su strain.

Sales and Marketing

We plan to become a fully-integrated

commercial biopharmaceutical company in the United States pursuing our mission of supporting and improving the lives of patients suffering

from cancer and rare diseases.

If approved by the FDA, we

plan to commercialize all of our current product candidates in the United States first and then in other geographies, if approved by the

regulatory authorities in those other locations.

As we advance TARA-002 and IV Choline Chloride through our respective clinical development

programs, we plan to grow our commercial organization in support of anticipated product launches.

The process for commercialization

of new drugs is very competitive, and we could potentially face worldwide competition from other pharmaceutical companies, biotechnology

companies and ultimately generic or biosimilar products.

Our potential competitors may develop or market therapies that are available

sooner, more clinically effective, safer or less expensive than any therapeutic products we develop.

Numerous companies are engaged in

the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are developing.

With respect to our lead product candidate, TARA-002, for the

treatment of NMIBC and LMs, the active ingredient in TARA-002 is a genetically distinct strain of Streptococcus pyogenes (group A, type

3) Su strain, which is inactivated during the manufacturing process.

TARA-002 is produced through a proprietary manufacturing process.

2 unchanged sentences

prevalence of the disease, TARA-002 is likely to have seven years of concurrent Orphan Drug Designation exclusivity for the treatment

are no approved pharmacotherapies currently available for the treatment of LMs and the current treatment options include a high-risk

surgical procedure and off-label use of sclerosants, including doxycycline, bleomycin, ethanol and sodium tetradecyl sulfate.

a number of drug development companies and academic researchers exploring oral and topical formulations of various agents for the treatment

of LMs including macrolides, phosphodiesterase inhibitors, and calcineurin/mTOR inhibitors.

There are no approved pharmacotherapies

currently available for the treatment of LMs in the U.S., and the current treatment options include a high-risk surgical procedure and

off-label use of sclerosants, including doxycycline, bleomycin, ethanol and sodium tetradecyl sulfate.

There are a number of drug development

companies and academic researchers exploring oral and topical formulations of various agents for the treatment of LMs including macrolides,

phosphodiesterase inhibitors, and calcineurin/mTOR inhibitors.

These are in early development.

TARA-002, if approved for the treatment of NMIBC, would be subject

to competition from existing treatment methods of surgery, chemotherapy and immunomodulatory therapy.

For example, the current standard

of care for NMIBC includes intravesical BCG TICE (manufactured by Merck & Co., Inc.).

Other products approved for the treatment of

NMIBC include Merck & Co., Inc.’s Keytruda, Endo International plc’s Valstar, and Ferring B.V.’s Adstiladrin.

product candidates in development include but may not be limited to Japanese BCG Laboratory’s BCG Tokyo, Pfizer Inc.’s Sasanlimab

in combination with BCG, ImmunityBio, Inc.’s VesAnktiva in combination with BCG, CG Oncology Inc.’s CG0070, enGene Inc.’s,

EG-70, Seagen Inc.’s PADCEV, Janssen’s TAR200 combined with gemcitabine plus or minus Cetrelimab, Urogen Pharma Ltd.’s

Jelmyto, Theralase Technologies Inc.’s Ruvidar, and Auro BioSciences, Inc.’s Aura-0011.

Additional pharmaceutical and biotechnology

companies with product candidates in development for the treatment of NMIBC include but may not be limited to Verity, AstraZeneca PLC,

Bristol-Myers Squibb Company, Roche Group, Asieris Pharmaceuticals, BeiGene, Ltd, NanOlogy, LLC, Linton Pharm Co., Ltd., Lindis Biotech

GmbH, Taizhou Hanzhong biomedical co.

TARA-002, if approved for

the treatment of NMIBC, would be subject to competition from existing treatment methods of surgery, chemotherapy and immunomodulatory

For example, the current standard of care for NMIBC includes intravesical BCG TICE (manufactured by Merck & Co., Inc.).

products approved for the treatment of NMIBC include Merck & Co., Inc.’s Keytruda, Endo International plc’s Valstar, and

Ferring B.V.’s Adstiladrin and ImmunityBio, Inc.’s VesAnktiva in combination with BCG.

Additional product candidates in development

include but may not be limited to Japanese BCG Laboratory’s BCG Tokyo, Pfizer Inc.’s Sasanlimab in combination with BCG, CG

Oncology Inc.’s CG0070, enGene Inc.’s, EG-70, Pfizer Inc.’s PADCEV, Janssen’s TAR200 combined with gemcitabine

plus or minus Cetrelimab, Urogen Pharma Ltd.’s Jelmyto, Theralase Technologies Inc.’s Ruvidar, and Auro BioSciences, Inc.’s

Additional pharmaceutical and biotechnology companies with product candidates in development for the treatment of NMIBC include

but may not be limited to Verity, AstraZeneca PLC, Bristol-Myers Squibb Company, Roche Group, Asieris Pharmaceuticals, BeiGene, Ltd, NanOlogy,

LLC, Linton Pharm Co., Ltd., Lindis Biotech GmbH, Taizhou Hanzhong biomedical co.

Ltd., Shionogi & Co.

Ltd., Rapamycin Holdings, Inc., Vaxiion Therapeutics Inc., Incyte Corporation,

LiPac Oncology, Inc., Anika Therapeutics Inc., Surge Pharmaceuticals Pvt.

Ltd., and Istari Oncology, Inc.

are no treatments currently available for patients on PN who are choline-deficient.

IV Choline Chloride is the only sterile injectable

form of choline chloride that can be combined with parenteral nutrition.

Further, the U.S.

Patent and Trademark Office, or USPTO, issued

to us Patent No.

US 11,311,503 claiming a sterile aqueous choline salt composition with a term expiring in 2041.

Regulation and Product Approval

FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among

other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,

storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting

of drugs and biologics such as those we are developing.

We, along with third-party contractors, will be required to navigate the various

preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to

conduct studies or seek approval or licensure of our product candidates.

the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA and biologics additionally under the

Public Health Services Act, or PHSA, as well as their respective implementing regulations.

The process required by the FDA before biopharmaceutical

product candidates may be marketed in the United States generally involves the following:

of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices,

or cGLP regulations;

to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant

changes are made;

by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;

of adequate and well-controlled human clinical trials to establish the safety and efficacy of a product candidate and the safety,

purity and potency of the proposed biologic product candidate for its intended purpose;

of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical trials that includes substantial evidence

of safety, purity and potency or efficacy from results of nonclinical testing and clinical trials;

determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the application for review;

completion of an FDA Advisory Committee review, if applicable;

completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced

to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with current Good Clinical Practices,

review and approval, or licensure, of the NDA or BLA to permit commercial marketing of the product for particular indications for

use in the United States.

and Clinical Development

to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA.

An IND is a request for authorization

from the FDA to administer an investigational new drug product to humans.

The central focus of an IND submission is on the general investigational

plan and the protocol(s) for clinical trials.

The IND also includes results of animal and in vitro studies assessing the toxicology,

pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate;

chemistry, manufacturing, and controls

Ltd., Rapamycin Holdings, Inc.,

Vaxiion Therapeutics Inc., Incyte Corporation, LiPac Oncology, Inc., Anika Therapeutics Inc., Surge Pharmaceuticals Pvt.

Ltd., and Istari

Oncology, Inc.

There are currently no available

PS formulations containing choline.

IV Choline Chloride is the only sterile injectable form of choline chloride that can be combined with

Further, the USPTO, issued to us Patent No.

US 11,311,503 claiming a sterile aqueous choline salt composition, and Patent No.

US 12,083,081

claiming a method of treating choline deficiency with a choline composition, each with a term expiring in 2041.

Government Regulation and Product Approval

The FDA and other regulatory

authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research,

development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution,

record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of drugs and biologics

such as those we are developing.

We, along with third-party contractors, will be required to navigate the various preclinical, clinical

and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek

approval or licensure of our product candidates.

In the United States, the

FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA and biologics additionally under the Public Health Services

Act, or PHSA, as well as their respective implementing regulations.

The application process and requirements for approval of BLAs are

very similar to those for NDAs.

Failure to comply with applicable U.S.

requirements may subject a company to a variety of administrative

or judicial sanctions, such as clinical hold, FDA refusal to file NDA/BLAs and/or to approve pending NDAs or BLAs, warning or untitled

letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties

and criminal prosecution.

The process required by the FDA before biopharmaceutical product candidates

may be marketed in the United States generally involves the following:

completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices, or cGLP regulations;

submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;

by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the clinical trial is commenced;

performance of adequate and well-controlled human clinical trials to

establish the safety and efficacy of a drug product candidate and the safety, purity and potency of a biologic product candidate for its

intended purpose;

preparation of and submission to the FDA of an NDA or BLA, including

a substantial application user fee unless a waiver applies, after completion of all pivotal clinical trials that includes substantial

evidence of safety, purity and potency or efficacy from results of non-clinical testing and clinical trials;

a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the application for review;

satisfactory completion of an FDA Advisory Committee review, if applicable;

satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with current Good Clinical Practices, or cGCP;

FDA review and approval, or licensure, of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States.

Preclinical and Clinical Development

Pharmaceutical product development

for a new product or certain changes to an approved product in the U.S.

typically involves preclinical laboratory and animal testing,

the submission to the FDA of an IND, which is a request for authorization from the FDA to administer an investigational product candidate

to humans, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication

for which FDA approval is sought.

Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time

required may vary substantially based upon the type, complexity, and novelty of the product or disease.

Preclinical tests include

laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential

safety and efficacy of the product.

The conduct of the preclinical tests must comply with federal regulations and requirements, including

Good Laboratory Practices, an international standard meant to ensure the presence of a standard quality system under which laboratory

work and non-clinical studies are conducted, recorded and archived.

The IND includes results

of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of

the product candidate;

chemistry, manufacturing, and controls information;

the general investigational plan;

the proposed protocol(s)

for clinical trials;

and any available human data or literature to support the use of the investigational product.

An IND must become effective

before human clinical trials may begin.

The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within

the 30-day time period, raises safety concerns or questions about the proposed clinical trial.

In such a case, the IND may be placed

on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin.

Long-term preclinical

tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted.

An IND must become

effective before human clinical trials may begin.

The IND automatically becomes effective 30 days after receipt by the FDA, unless the

FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial.

In such a case, the IND may

be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial

Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.

trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in

accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation

in any clinical trial.

Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the

parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.

A separate submission to the existing IND

must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.

an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and

its informed consent form before the clinical trial begins at that site, and must monitor the trial until completed.

Clinical trials involve the administration of the investigational

product to human subjects under the supervision of qualified investigators in accordance with GCPs, an international standards designed

to protect the rights and health of patients which includes the requirement that all research subjects provide their informed consent

for their participation in any clinical trial, and to define the roles, qualifications and responsibilities of clinical trial sponsors,

administrators and monitors.

Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical

trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.

A separate submission to the existing

IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.

an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its

informed consent form before the clinical trial begins at that site, and must monitor the clinical trial until completed.

Regulatory authorities,

the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed

to an unacceptable health risk or that the trial is unlikely to meet its stated objectives.

Some studies also include oversight by an

independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides

authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and

may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration

There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.

clinical trials are typically conducted in three sequential phases that may overlap.

to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives.

Some studies also include oversight

by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides

authorization for whether or not a clinical trial may move forward at designated check points based on access to certain data from the

clinical trial and may recommend that the clinical trial be stopped if it determines that there is an unacceptable safety risk for subjects

or other grounds, such as no demonstration of efficacy.

There are also requirements governing the reporting of ongoing clinical trials

and clinical trial results to public registries.

Human clinical trials are

typically conducted in three sequential phases that may overlap.

1—The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition.

These trials are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational

product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.

2—The investigational product is administered to a limited patient population with a specified disease or condition to evaluate

the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.

Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

3—The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically

significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical

These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to

provide an adequate basis for product approval.

some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain

more information about the product.

These so-called Phase 4 trials may be made a condition to approval of the NDA or BLA.

with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics

of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP

requirements.

The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among

other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the

safety, purity and potency.

Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to

demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

Submission, Review and Approval

successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,

nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for

one or more indications.

The NDA or BLA must include all relevant data available from pertinent preclinical and clinical trials, including

negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry,

manufacturing, controls, and proposed labeling, among other things.

The submission of an NDA or BLA requires payment of a substantial

application user fee to the FDA, unless a waiver or exemption applies.

an NDA or BLA has been submitted, the FDA’s goal is to review standard applications within ten months after it accepts the application

for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing.

standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification.

The FDA reviews the application to determine, among other things, whether a product is safe, pure and potent and the facility in which

it is manufactured, processed, packed, or held meets standards designed to assure the product’s continued safety, purity and potency.

The FDA may convene an advisory committee to provide clinical insight on application review questions.

Before approving an NDA or BLA,

the FDA will typically inspect the facility or facilities where the product is manufactured.

The FDA will not approve an application

unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure

consistent production of the product within required specifications.

Additionally, before approving an NDA or BLA, the FDA will typically

inspect one or more clinical sites to assure compliance with GCP.

If the FDA determines that the application, manufacturing process or

manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing

or information.

Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application

does not satisfy the regulatory criteria for approval.

FDA may issue an approval letter or a Complete Response letter.

An approval letter authorizes commercial marketing of the product with

specific prescribing information for specific indications.

A Complete Response letter will describe all of the deficiencies that the

FDA has identified in the NDA or BLA.

In issuing the Complete Response letter, the FDA may recommend actions that the applicant might

take to place the application in condition for approval, including requests for additional information or clarification.

delay or refuse approval of an application if applicable regulatory criteria are not satisfied, require additional testing or information

and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.

regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the

indicated uses for which such product may be marketed.

For example, the FDA may impose a Risk Evaluation and Mitigation Strategy, or

REMS, to ensure the benefits of the product outweigh its risks.

A REMS is a safety strategy to manage a known or potential serious risk

associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include

medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries

and other risk minimization tools.

The FDA also may condition approval on, among other things, changes to proposed labeling or the development

of adequate controls and specifications.

Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing

requirements is not maintained or if problems occur after the product reaches the marketplace.

The FDA may require one or more Phase

4 post-market trials and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization,

and may limit further marketing of the product based on the results of these post-marketing trials.

Drug Designation

the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which

is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United

States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic

for this type of disease or condition will be recovered from sales in the United States for that drug or biologic.

Orphan designation

must be requested before submitting an NDA or BLA.

After the FDA grants orphan designation, the generic identity of the therapeutic agent

and its potential orphan use are disclosed publicly by the FDA.

The orphan drug designation does not convey any advantage in, or shorten

the duration of, the regulatory review or approval process.

a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation,

the product is entitled to orphan exclusivity, which means that the FDA may not approve any other applications, including a full NDA

or BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical

superiority to the product with orphan drug exclusivity.

Orphan exclusivity does not prevent FDA from approving a different drug or biologic

for the same disease or condition, or the same drug or biologic for a different disease or condition.

Among the other benefits of orphan

drug designation are tax credits for certain research and a waiver of the BLA application fee.

designated orphan product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which

it received orphan designation.

In addition, exclusive marketing rights in the United States may be lost if the FDA later determines

that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product

to meet the needs of patients with the rare disease or condition.

FDA incentivizes the development of drugs and biologics that meet the definition of a “rare pediatric disease” defined to

mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged

from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the

United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for

such disease or condition will be received from sales in the United States of such drug.

The sponsor of a product candidate for a rare

pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic

application after the date of approval of the rare pediatric disease drug product, referred to as a priority review voucher, or PRV.

A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or BLA.

received, it may be sold or transferred an unlimited number of times.

Congress has extended the PRV program until September 30,

2024, with the potential for PRVs to be granted until September 30, 2026.

Post-Approval

products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,

among other things, requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences,

periodic reporting, product sampling and distribution, and advertising and promotion of the product.

After approval, most changes to

the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval.

are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA or

Biopharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain

state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which

impose certain procedural and documentation requirements upon sponsors and their third-party manufacturers.

Changes to the manufacturing

process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented.

FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon sponsor

and third-party manufacturers.

Accordingly, manufacturers must continue to expend time, money and effort in the area of production and

quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product

reaches the market.

Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity

or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved

labeling to add new safety information;

These clinical trials are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the

investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.

Phase 2—The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.

Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

Phase 3—The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites.

These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.

In most cases the FDA requires two adequate and well-controlled

Phase 3 clinical trials to demonstrate the efficacy of a drug.

A single Phase 3 trial with other confirmatory evidence may be sufficient

in rare instances, including (1) where the study is a large multicenter clinical trial demonstrating internal consistency and a statistically

very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially

serious outcome and confirmation of the result in a second clinical trial would be practically or ethically impossible or (2) when in

conjunction with confirmatory evidence.

In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials

after a product is approved to gain more information about the product.

These post-approval trials may be made a condition to approval

of the NDA or BLA.

Concurrent with clinical trials, companies may complete additional animal studies and develop additional information

about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial

quantities in accordance with cGMP requirements.

The manufacturing process must be capable of consistently producing quality batches of

the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final

product, or for biologics, the safety, purity and potency.

Additionally, appropriate packaging must be selected and tested and stability

studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

In addition, the sponsor of an investigational drug in a Phase 2 or

Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its

policy on evaluating and responding to requests for expanded access to such investigational drug.

Application Submission, Review and Approval

Assuming successful completion of all required testing in accordance

with all applicable regulatory requirements, the results of product development, non-clinical studies and clinical trials are submitted

to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications in the U.S.

The NDA or BLA must

include all relevant data available from all preclinical and clinical trials, including negative or ambiguous results as well as positive

findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling,

among other things.

The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver

or exemption applies.

These fees are typically increased annually.

The FDA has 60 days from its receipt of an NDA or BLA to determine

whether the application will be filed based on the FDA’s determination that it is adequately organized and sufficiently complete

to permit substantive review.

Once the submission is filed, the FDA begins an in-depth review.

For new molecular entities, the FDA’s

goal is to review standard applications within ten months after it files the application, or, if the application qualifies for priority

review, six months after the FDA files the application.

In both standard and priority reviews, the review process may be extended by FDA

requests for additional information or clarification.

The FDA reviews the application to determine, among other things, whether a product

is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the

product’s continued safety, purity and potency.

The FDA may convene an advisory committee – typically a panel that includes

clinicians, statisticians and other experts – to provide insight on application review questions.

The FDA is not bound by the recommendation

of the advisory committee, but generally follows such recommendation.

Before approving an NDA or BLA, the FDA will typically inspect the

facility or facilities where the product is manufactured.

The FDA will not approve an application unless it determines that the manufacturing

processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required

specifications.

Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance

If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline

the deficiencies in the submission and often will request additional testing or information.

Notwithstanding the submission of any requested

additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

The FDA will issue an approval letter or a Complete Response letter.

An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.

Response letter will describe all of the deficiencies that the FDA has identified in the NDA or BLA.

In issuing the Complete Response

letter, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests

for additional information or clarification.

The FDA may delay or refuse approval of an application if applicable regulatory criteria

are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety

or efficacy of a product.

If, or when, deficiencies outlined in a Complete Response letter have been addressed to the FDA’s satisfaction

in a resubmission of the NDA or BLA, the FDA will issue an approval letter.

The FDA has committed to reviewing such resubmissions in two

or six months depending on the type of information included.

As a condition of NDA or

BLA approval, the FDA may impose limitations on the indicated uses for which such product may be marketed.

For example, the FDA may impose

a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks.

A REMS is a safety strategy

to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines

by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as

restricted distribution methods, patient registries and other risk minimization tools.

The FDA also may condition approval on, among other

things, changes to proposed labeling or the development of adequate controls and specifications.

Once approved, the FDA may withdraw the

product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches

the marketplace.

The FDA may require one or more post-approval trials and surveillance to further assess and monitor the product’s

safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing

Disclosure of Clinical

Trial Information

Sponsors of clinical trials of FDA regulated products, including

drugs, are required to register and disclose certain clinical trial information.

Information related to the product, patient population,

phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration.

Sponsors are also obligated to discuss the results of their clinical trials after completion.

Disclosure of the results of these clinical

trials can be delayed in certain circumstances for up to two years after the date of completion of the clinical trial.

Competitors may

use this publicly available information to gain knowledge regarding the progress of development programs.

The government recently released

a regulation and policy to expand and enhance the requirements related to registering and reporting the results of clinical trials, which

may result in greater enforcement of these requirements in the future.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation

to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals

in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost

of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from

sales in the United States for that drug or biologic.

Orphan Drug Designation must be requested before submitting an NDA or BLA.

the FDA grants Orphan Drug Designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly

Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval

If a product that has Orphan Drug Designation subsequently receives

the first FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity, which means that

the FDA may not approve any other applications, including a full NDA or BLA, to market the same product for the same indication for seven

years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.

exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic

for a different disease or condition.

Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver

of the BLA application fee.

A designated orphan product

may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received Orphan Drug Designation.

In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation

was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients

with the rare disease or condition.

Rare Pediatric Disease Priority Review Voucher

The FDA incentivizes the

development of drugs and biologics that meet the definition of a “rare pediatric disease” defined to mean a serious or life-threatening

disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease

affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no

reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received

from sales in the United States of such drug.

The sponsor of a product candidate granted Rare Pediatric Disease Designation may be eligible

for a voucher that can be used to obtain a priority review for a subsequent NDA or BLA after the date of approval of the designated Rare

Pediatric Disease drug product, referred to as a priority review voucher, or PRV.

To receive a Rare Pediatric Disease PRV, a sponsor must

notify the FDA, upon submission of the NDA or BLA, of its intent to request a voucher.

If the FDA determines that the NDA or BLA is a

Rare Pediatric Disease product application, and if the NDA or BLA is approved, the FDA will award the sponsor of the application a PRV

upon approval of the NDA or BLA.

The FDA may revoke a Rare Pediatric Disease PRV if the product for which it was awarded is not marketed

within 365 days of the product’s approval.

The sponsor submitting the PRV must notify the FDA of is intent to submit

the voucher with the NDA or BLA at least 90 days prior to submission of the NDA or BLA and must pay a priority review user fee in addition

to any other required user fee.

The FDA must take action on an NDA or BLA under priority review within six months of the FDA’s filing

of the NDA or BLA.

A Rare Pediatric Disease Designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA

If a PRV is received, it may be sold or transferred an unlimited number of times prior to its redemption.

The Rare Pediatric Disease PRV Program has always had a scheduled

sunset date established in the law.

Under the current provisions in the law, as amended by the Continuing Appropriations and Extensions

Act, 2025, the Rare Pediatric Disease PRV Program will begin to sunset after December 20, 2024, which means that although Congress has

extended the law in the past, and has proposed extending it again, it has not yet done so.

Thus, after December 20, 2024, the FDA may

only award a PRV for an approved Rare Pediatric Disease product application if the sponsor has received Rare Pediatric Disease Designation

for the product by December 20, 2024, and the product is approved by September 30, 2026.

Accordingly, without further statutory amendments,

a drug for which the FDA has granted Rare Pediatric Disease Designation after December 20, 2024 may not be awarded a Rare Pediatric Disease

PRV even if approved by September 30, 2026, and the FDA may not award any Rare Pediatric Disease PRVs after September 30, 2026.

Fast Track Designation

Under the FDA’s Fast Track program, the sponsor of a new

drug candidate may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or

after, the submission of the IND for the drug candidate.

The FDA must determine if the drug candidate qualifies for Fast Track Designation

within 60 days of receipt of the sponsor’s request.

Fast Track Designation is intended to facilitate development and expedite review

of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously.

If a submission

is granted Fast Track Designation, the sponsor may engage in more frequent interactions with the FDA, and the FDA may review sections

of the NDA or BLA before the full application is complete.

This rolling review is available if, in agreement with the FDA, the applicant

provides a schedule for the submission of the remaining information.

However, the FDA does not start the review clock for the application

until the last section of the NDA or BLA is submitted.

Fast Track Designation may be withdrawn by the FDA at any time if they believe

that the designation is no longer supported by data emerging data in the development process.

Breakthrough Therapy Designation

Additionally, a drug candidate may be eligible for designation

as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs or biologics, to treat a serious

or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently

approved therapies on one or more clinically significant endpoints.

The FDA expects that such evidence generally would be derived from

early phase clinical trials such as Phase 1 or Phase 2 clinical trials.

For purposes of Breakthrough Therapy Designation, preliminary

clinical evidence refers to evidence that is sufficient to indicate that the drug may demonstrate substantial improvement in effectiveness

or safety over available therapies.

The FDA must determine if the product candidate qualifies for Breakthrough Therapy Designation within

60 days of receipt of the sponsor’s request.

The FDA may take certain actions with respect to breakthrough therapies, including

holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development

and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking

other steps to design the clinical studies in an efficient manner.

Breakthrough Therapy Designation may be withdrawn by the FDA at any

time if they believe that the designation is no longer supported by emerging data in the development process.

Post-Approval Requirements

Any products manufactured

or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,

requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences, periodic reporting,

product sampling and distribution, and advertising and promotion of the product.

After approval, most changes to the approved product,

such as adding new indications or other labeling claims, are subject to prior FDA review and approval.

There also are continuing user

fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA.

Biopharmaceutical

manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are

subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural

and documentation requirements upon sponsors and their third-party manufacturers.

Changes to the manufacturing process are strictly regulated,

and, depending on the significance of the change, may require prior FDA approval before being implemented.

FDA regulations also require

investigation and correction of any deviations from cGMP and impose reporting requirements upon sponsor and third-party manufacturers.

Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance

with cGMP and other aspects of regulatory compliance.

The FDA may withdraw approval

if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.

Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with

manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new

safety information;

imposition of post-market studies or clinical trials to assess new safety risks;

or imposition

of distribution restrictions or other restrictions under a REMS program.

or imposition of distribution restrictions

or other restrictions under a REMS program.

Other potential consequences include, among other things:

on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information,

issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications

containing warnings or other safety information about the product, or complete withdrawal of the product from the market or product

warning or untitled letters or holds on post-approval clinical trials;

of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product

seizure or detention, or refusal of the FDA to permit the import or export of products;

consent decrees or the imposition of civil or criminal penalties.

FDA closely regulates the marketing, labeling, advertising and promotion of biopharmaceuticals.

A company can make only those claims

relating to safety and efficacy, purity and potency of a biopharmaceutical that are approved by the FDA and in accordance with the provisions

of the approved label.

restrictions on the marketing or manufacturing of a product, mandated

modification of promotional materials or issuance of corrective information, issuance by the FDA or other regulatory authorities of safety

alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about

the product, or complete withdrawal of the product from the market or product recalls;

fines, warning or untitled letters or holds on post-approval clinical trials;

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;

product seizure or detention, or refusal of the FDA to permit the import or export of products;

injunctions, consent decrees or the imposition of civil or criminal penalties.

The FDA closely regulates

the marketing, labeling, advertising and promotion of biopharmaceuticals.

A company can make only those claims relating to safety and

efficacy, purity and potency of a biopharmaceutical that are approved by the FDA and in accordance with the provisions of the approved

The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising

and potential civil and criminal penalties.

Physicians may prescribe legally available products for uses that are not described in the

product’s labeling and that differ from those approved by the FDA.

Failure to comply

with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil

and criminal penalties.

Physicians may prescribe legally available products for uses that are not described in the product’s labeling

and that differ from those approved by the FDA.

Such off-label uses are common across medical specialties.

may believe that such off-label uses are the best treatment for many patients in varied circumstances.

The FDA does not regulate the

behavior of physicians in their choice of treatments.

The FDA does, however, restrict manufacturer’s communications on the subject

of off-label use of their products.

and Reference Product Exclusivity

Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or ACA, signed into law in

2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval

pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.

a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe.

The FDA has issued

several guidance documents outlining its approach to the review and approval of biosimilars.

Biosimilarity,

which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of

safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials.

Interchangeability

requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the

same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,

the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety

risks or risks of diminished efficacy relative to exclusive use of the reference biologic.

Complexities associated with the larger, and

often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant

hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.

the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference

product was first licensed by the FDA.

In addition, the approval of a biosimilar product may not be made effective by the FDA until 12

years from the date on which the reference product was first licensed.

During this 12-year period of exclusivity, another company may

still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s

own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its

The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.

At this juncture, it

is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which

are governed by state pharmacy law.

BPCIA is complex and continues to be interpreted and implemented by the FDA.

In addition, recent government proposals have sought to

reduce the 12-year reference product exclusivity period.

Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions,

have also been the subject of recent litigation.

As a result, the ultimate impact, implementation, and impact of the BPCIA is subject

to significant uncertainty.

Healthcare Laws and Compliance Requirements

the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition

to the FDA, including but not limited to, the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S.

of Health and Human Services, or HHS, (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and

Service Administration), the U.S.

Physicians may believe that

such off-label uses are the best treatment for many patients in varied circumstances.

The FDA does not regulate the behavior of physicians

in their choice of treatments.

The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of

their products.

Additional Controls for Biologics

To help reduce the increased

risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes

cannot be precisely defined.

The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where

there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and

to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United

After a BLA is approved,

the product may also be subject to official lot release as a condition of approval.

As part of the manufacturing process, the manufacturer

is required to perform certain tests on each lot of the product before it is released for distribution.

If the product is subject to official

release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary

of the lot manufacturing history and the results of all of the manufacturer’s tests performed on the lot.

The FDA may also perform

certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for

distribution.

In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and

effectiveness of biological products.

As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that

arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.

The Hatch-Waxman Amendments

Orange Book listing

In seeking approval for a

drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant’s product.

Upon approval

of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved Drug Products with

Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Drugs listed in the Orange Book can, in turn, be cited by potential

generic competitors in support of approval of an abbreviated new drug application, or ANDA.

An ANDA provides for marketing of a drug product

that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence

testing to be therapeutically equivalent to the listed drug.

Other than the requirement for bioequivalence testing, ANDA applicants are

not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product.

Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug and can often be substituted

by pharmacists under prescriptions written for the original listed drug.

The ANDA applicant is required to certify certain statements to the

FDA with respect to any patents listed for the approved product in the FDA’s Orange Book.

Specifically, the applicant must certify

that (i) the required patent information has not been filed;

(ii) the listed patent has expired;

(iii) the listed patent has not expired

but will expire on a particular date and approval is sought after patent expiration;

or (iv) the listed patent is invalid or will not

be infringed by the new product.

The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA

label does not contain (or carve out) any language regarding the patented method-of-use rather than certify to a listed method-of-use

If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents

claiming the referenced product have expired.

A certification that the new product will not infringe the already approved product’s

listed patents, or that such patents are invalid, is called a Paragraph IV certification.

If the ANDA applicant has provided a Paragraph

IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once

the ANDA has been accepted for filing by the FDA.

The NDA and patent holders may then initiate a patent infringement lawsuit in response

to the notice of the Paragraph IV certification.

The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph

IV certification automatically prevents the FDA from approving the ANDA until the earliest of 30 months, expiration of the patent, settlement

of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.

The ANDA application also

will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.

Upon NDA approval of a

new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other NDA, that

drug receives five years of marketing exclusivity during which the FDA cannot receive any ANDA seeking approval of a generic version

of that drug.

An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed.

no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the

expiration of the exclusivity period.

Certain changes to a drug, such as the addition of a new indication to the package insert, can

be the subject of a three-year exclusivity period if the application contains reports of new clinical investigations (other than

bioavailability studies) conducted or sponsored by the sponsor that were essential to the approval of the application.

cannot approve an ANDA for a generic drug that includes the change during the exclusivity period.

Patent term extension

After NDA approval, owners of relevant drug patents may apply for up

to a five-year patent extension.

The allowable patent term extension is calculated as half of the drug’s testing phase (the time

between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval up to a maximum

of five years).

The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence.

patent term after the extension may not exceed 14 years from the date of product approval.

Only one patent applicable to an approved drug

is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may

be extended, and the application for the extension must be submitted prior to the expiration of the patent.

For patents that might expire

during the application phase, the patent owner may request an interim patent extension.

An interim patent extension increases the patent

term by one year and may be renewed up to four times.

For each interim patent extension granted, the post-approval patent extension is

reduced by one year.

The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension

is being sought is likely.

Interim patent extensions are not available for a drug for which an NDA has not been submitted.

Biosimilars and Reference Product Exclusivity

The Patient Protection and

Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or ACA, signed into law in 2010, includes a subtitle

called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological

products that are biosimilar to or interchangeable with an FDA-approved reference biological product.

To date, numerous biosimilars and

several interchangeable biosimilars have been licensed under the BPCIA and approved in Europe.

The FDA has issued several guidance documents

outlining its approach to the review and approval of biosimilars and interchangeable biosimilars.

Biosimilarity, which requires

that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences

between the biological product and the reference product in terms of safety, purity, and potency, must be shown through analytical studies,

animal studies, and a clinical trial or trials unless the Secretary of Health and Human Services waives a required element.

product may be deemed interchangeable with a previously approved product if it is biosimilar to the reference product and the product

demonstrates that it can be expected to produce the same clinical results as the reference product in any given patient and, for products

that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one

has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference

Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes

by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still

being worked out by the FDA.

Under the BPCIA, an application

for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed

In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which

the reference product was first licensed.

During this 12-year period of exclusivity, another company may still market a competing version

of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data

and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.

The BPCIA also

created certain exclusivity periods for biosimilars approved as interchangeable products.

At this juncture, it is unclear whether products

deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy

The BPCIA is complex and

continues to be interpreted and implemented by the FDA and litigated in the courts.

Pediatric Information

Under the Pediatric Research

Equity Act, or PREA, NDAs, BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the drug for

the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation

for which the drug is safe and effective.

The FDA may grant full or partial waivers, or deferrals, for submission of data.

exceptions, the PREA does not apply to any drug for an indication for which Orphan Drug Designation has been granted.

The Best Pharmaceuticals

for Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity—patent or nonpatent—for a drug and

BLA holders a six-month extension of market exclusivity for biologics if certain conditions are met.

Conditions for exclusivity include

FDA’s determination that information relating to the use of a new drug or biologic in the pediatric population may produce health

benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting

on, the requested studies within the statutory timeframe.

Applications under the BPCA are treated as priority applications, with all of

the benefits that designation confers.

Healthcare Laws and Compliance

In the United States, our

current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including

but not limited to, the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S.

Department of Health and Human

Services, or HHS, (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration),

Department of Justice, or DOJ and individual U.S.

Attorney offices within the DOJ, and state and local

For example, our clinical research, sales, marketing and scientific/educational grant programs will need to comply with

the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of the Health

Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.

federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting

or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing,

leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare,

Medicaid or other federal healthcare programs.

Attorney offices within the DOJ, and state and local governments.

our clinical research, sales, marketing and scientific/educational grant programs will need to comply with the anti-fraud and abuse provisions

of the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability

Act, or HIPAA, and similar state laws, each as amended, as applicable.

The federal Anti-Kickback

Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any

remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering

or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other

federal healthcare programs.

The term remuneration has been interpreted broadly to include anything of value.

The Anti-Kickback

Statute has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers,

and formulary managers on the other.

There are a number of statutory exceptions and regulatory safe harbors protecting some common activities

from prosecution.

The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be

intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe

Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make

the conduct per se illegal under the Anti-Kickback Statute.

Instead, the legality of the arrangement will be evaluated on a case-by-case

basis based on a cumulative review of all of its facts and circumstances.

Our practices may not in all cases meet all of the criteria

for protection under a statutory exception or regulatory safe harbor.

Additionally,

the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the

Health Care and Education Reconciliation Act of 2010, or the Affordable Care Act, to a stricter standard such that a person or entity

no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback

Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA (discussed below).

federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties and can be enforced by

private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing

to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs,

such as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false

or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation

to pay money to the federal government.

The Anti-Kickback Statute

has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary

managers on the other.

There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.

The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce

prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor.

meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se

illegal under the Anti-Kickback Statute.

Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a

cumulative review of all of its facts and circumstances.

Our practices may not in all cases meet all of the criteria for protection under

a statutory exception or regulatory safe harbor.

Additionally, the intent

standard under the Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity no longer needs to

have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

In addition, the ACA codified

case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false

or fraudulent claim for purposes of the federal False Claims Act, or the FCA (discussed below).

The federal false claims,

including the FCA, and civil monetary penalty laws, which imposes significant penalties and can be enforced by private citizens through

civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false

or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare and

Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to

the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the

federal government.

A claim includes “any request or demand” for money or property presented to the U.S.

For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly

providing free product to customers with the expectation that the customers would bill federal programs for the product.

Other companies

have been prosecuted for causing false claims to be submitted because of the companies’ marketing of the product for unapproved,

off-label, and thus generally non-reimbursable, uses.

created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute,

a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned

by, or under the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a

criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or

device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment

for healthcare benefits, items or services.

Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain

healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific

intent to violate it in order to have committed a violation.

many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed

under Medicaid and other state programs, or, in several states, apply regardless of the payor.

may be subject to data privacy and security regulations by both the federal government and the states in which it conducts business.

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations,

imposes requirements on “covered entities,” including certain healthcare providers, health plans, and healthcare clearinghouses,

as well as their respective “business associates” that create, receive, maintain or transmit individually identifiable health

information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission

of individually identifiable health information.

Among other things, HITECH makes HIPAA’s privacy and security standards directly

applicable to business associates, independent contractors, or agents of covered entities that receive or obtain protected health information

in connection with providing a service on behalf of a covered entity.

HITECH also created four new tiers of civil monetary penalties,

amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority

to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys’ fees and costs associated

with pursuing federal civil actions.

In addition, many state laws govern the privacy and security of health information in specified

circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive

effect than HIPAA, thus complicating compliance efforts.

may develop products that, once approved, may be administered by a physician.

For instance,

historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product

to customers with the expectation that the customers would bill federal programs for the product.

Other companies have been prosecuted

for causing false claims to be submitted because of the companies’ marketing of the product for unapproved, off-label, and thus

generally non-reimbursable, uses.

HIPAA created additional

federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to

defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under

the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation

of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact

or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,

items or services.

Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA

such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have

committed a violation.

Also, many states have similar,

and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and

other state programs, or, in several states, apply regardless of the payor.

We may be subject to data

privacy and security regulations by both the federal government and the states in which it conducts business.

HIPAA, as amended by the

Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements

on “covered entities,” including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their

respective “business associates” that create, receive, maintain or transmit individually identifiable health information for

or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually

identifiable health information.

Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to

business associates, independent contractors, or agents of covered entities that receive or obtain protected health information in connection

with providing a service on behalf of a covered entity.

HITECH also created four new tiers of civil monetary penalties, amended HIPAA

to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file

civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys’ fees and costs associated with pursuing

federal civil actions.

In addition, many state laws govern the privacy and security of health information in specified circumstances,

many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than

HIPAA, thus complicating compliance efforts.

We may develop products that,

once approved, may be administered by a physician.

Under currently applicable U.S.

law, certain products not

usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B.

Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and

covers outpatient services and supplies, including certain biopharmaceutical products, that are medically necessary to treat a beneficiary’s

health condition.

As a condition of receiving Medicare Part B reimbursement for a manufacturer’s eligible drugs, the manufacturer

is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing

The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement

with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished

to Medicaid patients.

Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the

addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average

sales price, or ASP, and best price.

law, certain products not usually self-administered

(including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B.

Medicare Part B is part of original

Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services

and supplies, including certain biopharmaceutical products, that are medically necessary to treat a beneficiary’s health condition.

As a condition of receiving Medicare Part B reimbursement for a manufacturer’s eligible drugs, the manufacturer is required to participate

in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program.

The Medicaid Drug

Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of

HHS as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished to Medicaid patients.

Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program.

In addition, many pharmaceutical

manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best

Penalties may apply in some cases when such metrics are not submitted accurately and timely.

these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors

and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than

in the United States.

It is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products in

the future and coverage and reimbursement under different federal healthcare programs are not always consistent.

Medicare reimbursement

rates may also reflect budgetary constraints placed on the Medicare program.

Additionally,

the federal Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require

that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid

or the Children’s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments

or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),

other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, or to entities or individuals

at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment

interests held by physicians and their immediate family members.

Further, these prices for drugs may

be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation

of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.

difficult to predict how Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and reimbursement

under different federal healthcare programs are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints

placed on the Medicare program.

Additionally, the federal

Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing regulations, require that certain manufacturers

of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health

Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value

made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare

professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, or to entities or individuals at the request

of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests

held by physicians and their immediate family members.

Failure to report accurately could result in penalties.

many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways,

are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.

order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale

distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products

into the state even if such manufacturers or distributors have no place of business within the state.

Some states also impose requirements

on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require

manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.

Several states and/or localities have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing

compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials

and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from

providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit

certain other sales and marketing practices.

All of our activities are potentially subject to federal and state consumer protection and

unfair competition laws.

business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor.

If our operations

are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental

regulations that apply to it, it may be subject to penalties, including without limitation, significant civil, criminal and/or administrative

penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid,

injunctions, private “qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to

allow it to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future

earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to

resolve allegations of non-compliance with these laws, and the curtailment or restructuring of its operations, any of which could adversely

affect our ability to operate our business and our results of operations.

Pricing and Reimbursement

uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval.

In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will

depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products.

In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers

and other organizations.

Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in

the United States, and commercial payors are critical to new product acceptance.

ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement for these

products and related treatments will be available from government health administration authorities, private health insurers and other

organizations.

Government authorities and other third-party payors, such as private health insurers and health maintenance organizations,

decide which therapeutics they will pay for and establish reimbursement levels.

Coverage and reimbursement by a third-party payor may

depend upon a number of factors, including the third-party payor’s determination that use of a therapeutic is:

covered benefit under its health plan;

effective and medically necessary;

for the specific patient;

In addition, many states

also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often

not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.

In order to distribute products

commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological

products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers

or distributors have no place of business within the state.

Some states also impose requirements on manufacturers and distributors to

establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new

technology capable of tracking and tracing product as it moves through the distribution chain.

Several states and/or localities have enacted

legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with

the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their

sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data

to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices.

All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.

Ensuring business arrangements

with third parties comply with applicable healthcare laws and regulations is a costly endeavor.

If our operations are found to be in violation

of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to

it, it may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages,

fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private

“qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to allow it to enter into

government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional

reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations

of non-compliance with these laws, and the curtailment or restructuring of its operations, any of which could adversely affect our ability

to operate our business and our results of operations.

Coverage, Pricing and Reimbursement

Significant uncertainty exists

as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval.

In the United States

and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the

extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products.

In the United States,

third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations.

Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial

payors are critical to new product acceptance.

Our ability to commercialize

any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments

will be available from government health administration authorities, private health insurers and other organizations.

Government authorities

and other third-party payors, such as private health insurers and health maintenance organizations, decide which therapeutics they will

pay for and establish reimbursement levels.

Coverage and reimbursement by a third-party payor may depend upon a number of factors, including

the third-party payor’s determination that use of a therapeutic is:

a covered benefit under its health plan;

safe, effective and medically necessary;

appropriate for the specific patient;

cost-effective;

experimental nor investigational.

cannot be sure that reimbursement will be available for any product that it commercializes and, if coverage and reimbursement are available,

what the level of reimbursement will be.

Coverage may also be more limited than the purposes for which the product is approved by the

FDA or comparable foreign regulatory authorities.

Reimbursement may impact the demand for, or the price of, any product for which we

obtain regulatory approval.

payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products,

therapies and services, in addition to questioning their safety and efficacy.

Obtaining reimbursement for our products may be particularly

difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician.

We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our

products, in addition to the costs required to obtain FDA approvals.

Our product candidates may not be considered medically necessary

or cost-effective.

Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming

and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the

use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained.

decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.

Further, one payor’s

determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.

third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our

investment in product development.

If reimbursement is not available or is available only at limited levels, we may not be able to successfully

commercialize any product candidate that it successfully develops.

pricing and reimbursement schemes exist in other countries.

In the European Union, governments influence the price of biopharmaceutical

products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost

of those products to consumers.

Some jurisdictions operate positive and negative list systems under which products may only be marketed

once a reimbursement price has been agreed.

To obtain reimbursement or pricing approval, some of these countries may require the completion

of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies.

states allow companies to fix their own prices for medicines but monitor and control company profits.

The downward pressure on health

care costs has become intense.

neither experimental nor investigational.

We cannot be sure that reimbursement

will be available for any product that it commercializes and, if coverage and reimbursement are available, what the level of reimbursement

Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory

Reimbursement may impact the demand for, or the price of, any product for which we obtain regulatory approval.

Third-party payors are increasingly

challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services,

in addition to questioning their safety and efficacy.

Obtaining reimbursement for our products may be particularly difficult because of

the higher prices often associated with branded drugs and drugs administered under the supervision of a physician.

We may need to conduct

expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to

the costs required to obtain FDA approvals.

Our product candidates may not be considered medically necessary or cost-effective.

coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that

could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a

payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained.

A payor’s decision to provide

coverage for a product does not imply that an adequate reimbursement rate will be approved.

Further, one payor’s determination to

provide coverage for a product does not assure that other payors will also provide coverage for the product.

Adequate third-party reimbursement

may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product

candidate that it successfully develops.

Different pricing and reimbursement

schemes exist in other countries.

In the European Union, governments influence the price of biopharmaceutical products through their pricing

and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers.

Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has

To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare

the cost effectiveness of a particular product candidate to currently available therapies.

Other member states allow companies to fix

their own prices for medicines but monitor and control company profits.

The downward pressure on health care costs has become intense.

As a result, increasingly high barriers are being erected to the entry of new products.

In addition, in

some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and

third-party payors fail to provide adequate coverage and reimbursement.

In addition, emphasis on managed care, the increasing influence

of health maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue

to increase, the pressure on healthcare pricing.

The downward pressure on the rise in healthcare costs in general, particularly prescription

medicines, medical devices and surgical procedures and other treatments, has become very intense.

Coverage policies and third-party reimbursement

rates may change at any time.

Even if favorable coverage and reimbursement status is attained for one or more products for which we receive

regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and

proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate

post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained.

policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems

with the stated goals of containing healthcare costs, improving quality and/or expanding access.

In the United States, the pharmaceutical

industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers.

Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise

described above, are the following:

annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents

apportioned among these entities according to their market share in some government healthcare programs;

increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the

average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs

at 100% of the Average Manufacturer Price, or the AMP;

a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D;

extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid

managed care organizations;

expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional

individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty

level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

expansion of the entities eligible for discounts under the 340B Drug Discount Program;

new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness

research, along with funding for such research;

expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers,

and enhanced penalties for noncompliance;

new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,

infused, instilled, implanted, or injected;

requirement to report certain financial arrangements with physicians and teaching hospitals;

requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;

establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower

Medicare and Medicaid spending;

licensure framework for follow on biologic products.

There remain legal and political

challenges to certain aspects of the Affordable Care Act.

Starting in January 2017, the Trump administration signed several executive

orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act.

2017, Congress repealed the tax penalty for an individual’s failure to maintain Affordable Care Act-mandated health insurance as

part of a tax reform bill.

Further, the 2020 federal spending package permanently eliminated the Affordable Care Act-mandated “Cadillac”

tax on high-cost employer-sponsored health coverage and medical device tax and also eliminated the health insurer tax.

In June 2021, the

Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety

because the “individual mandate” was repealed by Congress.

Thus, the Affordable Care Act will remain in effect in its current

Further, prior to the U.S.

Supreme Court ruling, in January 2021, President Biden issued an executive order to initiate a special

enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace.

The executive order

also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,

including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that

create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act.

It is possible

that the Affordable Care Act will be subject to judicial or Congressional challenges in the future.

It is unclear how such challenges

and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.

anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward

pressure on coverage and the price that we receive for any approved product, and could seriously harm our business.

Any reduction in

reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.

The implementation

of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or

commercialize our products.

Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully

develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product

Further legislation or regulation

could be passed that could harm our business, financial condition and results of operations.

Other legislative changes have been proposed

and adopted since the Affordable Care Act was enacted.

For example, in August 2011, President Obama signed into law the Budget Control

Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in

spending reductions.

The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion

for fiscal years 2012 through 2021, triggering the legislation’s automatic reduction to several government programs.

This includes

aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013

and will stay in effect through 2031 unless additional Congressional action is taken.

However, COVID-19 pandemic relief legislation suspended

the 2% Medicare sequester from May 1, 2020 through March 31, 2021.

Under current legislation, the actual reduction in Medicare payments

varied from 1% in 2022 to up to 3% in the final fiscal year of this sequester.

Additionally, in March 2021, President Biden signed the

American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, which was previously set at 100% of

a drug’s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024.

Additionally, there has been

increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.

Specifically, there

have been several recent U.S.

Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency

to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient

programs, and reform government program reimbursement methodologies for drugs.

For example, the Trump administration used several means

to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives.

example, in July 2020 and September 2020, the Trump administration announced several executive orders related to prescription drug pricing

that attempt to implement several of the administration’s proposals.

The FDA also released a final rule and guidance implementing

a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada.

Further, in November 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection

for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers,

unless the price reduction is required by law.

The implementation of the rule was delayed by the Biden administration from January 1,

2022 to January 1, 2023 in response to ongoing litigation.

The rule also created a new safe harbor for price reductions reflected at the

point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the

implementation of which also was delayed until January 1, 2023.

In January 2024, the FDA authorized the state of Florida to import certain

prescription drugs from Canada, and future authorizations may occur.

In July 2021, the Biden administration released an executive order,

“Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs.

In response to Biden’s

executive order, in September 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug

pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles.

No legislation

or administrative actions have been finalized to implement these principles.

In addition, on August 16, 2022, President Biden signed into

law the Inflation Reduction Act of 2022, which, among other things, contains substantial drug pricing reforms that will reduce drug spending

by the federal government.

For example, the Inflation Reduction Act of 2022 limits the prices paid by Medicare for various prescription

drugs and requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by Medicare

beneficiaries.

Although the effect of the Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is

not yet known, the Inflation Reduction Act of 2022 could affect the prices we can charge and the reimbursement we can receive for our

product candidates, if approved, thereby reducing our profitability.

We also expect that additional state and federal healthcare reform

measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare

products and services, which could result in reduced demand for our product candidates if approved or additional pricing pressures.

Foreign Corrupt Practices Act

Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S.

individual or business from paying, offering, or authorizing payment or

offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing

any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business.

also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain

books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to

devise and maintain an adequate system of internal accounting controls for international operations.

addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational

Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business.

other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated

by, our operations.

If our operations result in contamination of the environment or expose individuals to hazardous substances, we could

be liable for damages and governmental fines.

We believe that we are in material compliance with applicable environmental laws and that

continued compliance therewith will not have a material adverse effect on our business.

We cannot predict, however, how changes in these

laws may affect our future operations.

are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices,

environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

We may incur significant

costs to comply with such laws and regulations now or in the future.

of December 31, 2023, we had 27 employees, 26 of whom were full-time employees and one of whom was a temporary employee.

As of December

31, 2023, 17 of our employees were engaged in research and development activities and 10 of our employees were engaged in business development,

legal, finance, market development, information systems, facilities, human resources or administrative support.

In addition, in some countries, cross-border imports

from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any

product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail

to provide adequate coverage and reimbursement.

In addition, emphasis on managed care, the increasing influence of health maintenance

organizations, and additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure

on healthcare pricing.

The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical

devices and surgical procedures and other treatments, has become very intense.

Coverage policies and third-party reimbursement rates may

change at any time.

Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory

approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Healthcare Reform

In the United States and

some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding

the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities,

and affect the ability to profitably sell product candidates for which marketing approval is obtained.

Among policy makers and payors

in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of

containing healthcare costs, improving quality and/or expanding access.

In the United States, the pharmaceutical industry has been a particular

focus of these efforts and has been significantly affected by major legislative initiatives.

For example, in March 2010, the ACA was enacted, which intended to

broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add

new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and

impose additional health policy reforms.

The ACA has substantially changed the way healthcare is financed by both governmental and private insurers,

and significantly impacts the U.S.

pharmaceutical industry.

Other legislative changes

have been proposed and adopted since the ACA was enacted.

For example, under the American Rescue Plan Act of 2021, effective January 1,

2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs has been eliminated.

Elimination of this cap has, in some cases, required pharmaceutical manufacturers to pay more in rebates than they have received on the

sale of products.

In addition, in 2024, CMS issued a final rule that decreased Medicare reimbursement for physician services by 2.8%,

effective January 1, 2025.

If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant

agencies, such as the FDA, to continue to function at current levels.

Several healthcare reform

proposals culminated in the enactment of the Inflation Reduction Act, or the IRA, in August of 2022, which, among other things, eliminated,

beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket costs and requiring

manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees’ prescription costs

for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached.

The IRA also allows HHS to directly

negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part

B and Part D.

The negotiated price may not exceed a statutory ceiling price.

Only high-expenditure single-source drugs that have been

approved for at least seven years (11 years for single-source biologics) are eligible to be selected by CMS for negotiation, with the

negotiated price taking effect two years after the selection year.

For 2026, the first year in which negotiated prices become effective,

CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each

product has been announced.

CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027.

an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years,

20 Part B or Part D drugs will be selected.

A drug or biological product that has an Orphan Drug Designation for only one rare disease

or condition will be excluded from the IRA’s price negotiation requirements, but will lose that exclusion if it receives designations

for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease

or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for

selection for negotiation.

The IRA also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate greater

than the rate of inflation, and in November 2024, CMS finalized regulations for the Medicare Part B and Part D inflation rebates.

IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.

IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.

Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties.

These provisions

may be subject to legal challenges.

For example, the provisions related to the negotiation of selling prices of high-expenditure single-source

drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers.

The outcome of these lawsuits is

uncertain, and some IRA drug discount provisions have not been challenged in litigation.

Thus, while it is unclear how the IRA will be

implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of pharmaceutical products.

At the state level, legislatures

are increasingly enacting legislation and implementing regulations designed to control pharmaceutical and biological product pricing,

including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure

and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

the FDA released a final rule in 2020 providing guidance for states to build and submit importation proposals for drugs from Canada, and

the FDA authorized the first such plan in Florida in 2024.

The Foreign Corrupt Practices Act

The Foreign Corrupt Practices

Act, or the FCPA, prohibits any U.S.

individual or business from paying, offering, or authorizing payment or offering of anything of value,

directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the

foreign entity in order to assist the individual or business in obtaining or retaining business.

The FCPA also obligates companies whose

securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately

and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system

of internal accounting controls for international operations.

Additional Regulation

In addition to the foregoing,

state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act,

the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business.

These and other laws govern our use,

handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations.

our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages

and governmental fines.

We believe that we are in material compliance with applicable environmental laws and that continued compliance

therewith will not have a material adverse effect on our business.

We cannot predict, however, how changes in these laws may affect our

future operations.

Other Regulations

We are also subject to numerous

federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection,

fire hazard control, and disposal of hazardous or potentially hazardous substances.

We may incur significant costs to comply with such

laws and regulations now or in the future.

As of December 31, 2024,

all of our employees were located in the United States.

None of our United States employees are represented by any collective bargaining

We believe that we maintain good relations with our employees.

January 9, 2020, Protara Therapeutics, Inc.

(formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc., or the Company

or Protara), and privately-held ArTara Subsidiary, Inc., or Private ArTara, completed the merger and reorganization, or the Merger, in

accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated September 23, 2019, or the Merger Agreement,

by and among the Company, Private ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of the Company, or Merger Sub, whereby

Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of the Company.

was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and

other factors.

were originally incorporated in Delaware in March 2006, and at that time, acquired Proteon Therapeutics, LLC, the predecessor of Protara,

which was formed in June 2001.

principal executive offices are located at 345 Park Avenue South, 3 rd Floor, New York, New York 10010, our telephone number

is (646) 844-0337 and our website address is www.protaratx.com.

The contents of our website are not incorporated into this Annual Report

on Form 10-K and our reference to the URL for our website is intended to be an inactive textual reference only.

The information contained

on, or that can be accessed through, our website is not a part of this document.

the context requires otherwise, references in this Annual Report on Form 10-K to “Protara”, “TARA”, “we”,

“us”, the “Company” and “our” refer to Protara Therapeutics, Inc.

(formerly ArTara Therapeutics,

Inc., formerly Proteon Therapeutics, Inc.) and our subsidiaries.

Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections

13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, will be made available free of charge on our

website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

we had 33 employees, 28 of whom were full-time employees and five of whom were temporary employees.

As of December 31, 2024, 20 of our

employees were engaged in research and development activities and 13 of our employees were engaged in business development, legal, finance,

market development, information systems, facilities, human resources or administrative support.

As of December 31, 2024, all of our employees

were located in the United States.

None of our United States employees are represented by any collective bargaining agreements.

that we maintain good relations with our employees.

Corporate Information

On January 9, 2020, Protara

Therapeutics, Inc.

(formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc., or the Company or Protara), and privately-held

ArTara Subsidiary, Inc., or Private ArTara, completed the merger and reorganization, or the Merger, in accordance with the terms of the

Agreement and Plan of Merger and Reorganization, dated September 23, 2019, or the Merger Agreement, by and among the Company, Private

ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of the Company, or Merger Sub, whereby Merger Sub merged with and into Private

ArTara, with Private ArTara surviving as a wholly owned subsidiary of the Company.

The Merger was structured as a reverse merger and Private

ArTara was determined to be the accounting acquirer based on the terms of the Merger and other factors.

We were originally incorporated

in Delaware in March 2006, and at that time, acquired Proteon Therapeutics, LLC, the predecessor of Protara, which was formed in June

Our principal executive offices

are located at 345 Park Avenue South, 3 rd Floor, New York, New York 10010, our telephone number is (646) 844-0337 and our website

address is www.protaratx.com.

The contents of our website are not incorporated into this Annual Report on Form 10-K and our reference

to the URL for our website is intended to be an inactive textual reference only.

The information contained on, or that can be accessed

through, our website is not a part of this document.

Unless the context requires

otherwise, references in this Annual Report on Form 10-K to “Protara”, “TARA”, “we”, “us”,

the “Company” and “our” refer to Protara Therapeutics, Inc.

(formerly ArTara Therapeutics, Inc., formerly Proteon

Therapeutics, Inc.) and our subsidiaries.

Available Information

Annual Reports on Form 10-K,

Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the

Securities Exchange Act of 1934, as amended, or the Exchange Act, will be made available free of charge on our website as soon as reasonably

practicable after we electronically file such material with, or furnish it to, the SEC.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business